

# Adrian F Hernandez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8802617/publications.pdf>

Version: 2024-02-01

871  
papers

55,389  
citations

1294

109  
h-index

2323

199  
g-index

951  
all docs

951  
docs citations

951  
times ranked

38088  
citing authors

#	ARTICLE	IF	CITATIONS
1	When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 108-115.	2.3	14
2	When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 116-121.	2.3	4
3	Association of Vasopressor Choice with Clinical and Functional Outcomes Following Moderate to Severe Traumatic Brain Injury: A TRACK-TBI Study. <i>Neurocritical Care</i> , 2022, 36, 180-191.	1.2	5
4	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 191-201.	0.7	6
5	Identifying Treatments for Stage C2 Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 34.	3.0	5
6	Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. <i>Diabetes Research and Clinical Practice</i> , 2022, 183, 109152.	1.1	2
7	Utilization of Brain Tissue Oxygenation Monitoring and Association with Mortality Following Severe Traumatic Brain Injury. <i>Neurocritical Care</i> , 2022, 36, 350-356.	1.2	12
8	Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. <i>ESC Heart Failure</i> , 2022, 9, 178-185.	1.4	3
9	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 370-384.	0.7	16
10	Achieving More Rapid Door-to-Needle Times and Improved Outcomes in Acute Ischemic Stroke in a Nationwide Quality Improvement Intervention. <i>Stroke</i> , 2022, 53, 1328-1338.	1.0	16
11	Dysglycemia and incident heart failure among blacks: The jackson heart study. <i>American Heart Journal</i> , 2022, 245, 1-9.	1.2	3
12	Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. <i>Thrombosis Research</i> , 2022, 211, 63-69.	0.8	1
13	Research Goes Red: Early Experience With a Participant-Centric Registry. <i>Circulation Research</i> , 2022, 130, 343-351.	2.0	6
14	Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 760.	3.8	28
15	The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from <sc>CHAMP-HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 762-770.	2.9	8
16	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 1063-1077.	0.7	23
17	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 184-197.	1.9	75
18	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790.	2.9	16

#	ARTICLE	IF	CITATIONS
19	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2022, 10, 198-210.	1.9	16
20	Racial/Ethnic Disparities in Healthcare Worker Experiences During the COVID-19 Pandemic: An Analysis of the HERO Registry. <i>EClinicalMedicine</i> , 2022, 45, 101314.	3.2	7
21	2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of Cardiac Failure</i> , 2022, 28, 810-830.	0.7	42
22	The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study. <i>Contemporary Clinical Trials</i> , 2022, 115, 106732.	0.8	2
23	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1757-1780.	1.2	314
24	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, 101161CIR0000000000001063.	1.6	756
25	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, 101161CIR0000000000001062.	1.6	133
26	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, e263-e421.	1.2	774
27	Patient partnership in cardiovascular clinical trials. <i>European Heart Journal</i> , 2022, 43, 1432-1437.	1.0	4
28	Multiple cardiac sensors for management of heart failure (MANAGE-HF) – Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 1245-1254.	0.7	22
29	Health System Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial. <i>Journal of Cardiac Failure</i> , 2022, , .	0.7	7
30	Poor Medication Adherence Is Associated With Worse Health Status In Heart Failure With Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, S119.	0.7	0
31	Quantitative Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients With Worsening Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 1469-1474.	0.7	4
32	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2058-2068.	1.2	41
33	Risk Factors and Neurological Outcomes Associated With Circulatory Shock After Moderate to Severe Traumatic Brain Injury: A TRACK-TBI Study. <i>Neurosurgery</i> , 2022, 91, 427-436.	0.6	5
34	The impact of COVID-19 on pragmatic clinical trials: lessons learned from the NIH Health Care Systems Research Collaboratory. <i>Trials</i> , 2022, 23, .	0.7	6
35	Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
36	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	10

#	ARTICLE	IF	CITATIONS
37	Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMPâ€œCHF. Journal of the American Heart Association, 2022, 11, .	1.6	3
38	Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. European Journal of Heart Failure, 2022, 24, 1614-1622.	2.9	15
39	Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). American Journal of Cardiology, 2022, 178, 11-17.	0.7	3
40	Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges. Clinical Trials, 2022, 19, 561-572.	0.7	2
41	Racial and Ethnic Differences in Health Care Utilization Following Severe Acute Brain Injury in the United States. Journal of Intensive Care Medicine, 2021, 36, 1258-1263.	1.3	10
42	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. ESC Heart Failure, 2021, 8, 662-669.	1.4	5
43	PCORnetâ€œ 2020: current state, accomplishments, and future directions. Journal of Clinical Epidemiology, 2021, 129, 60-67.	2.4	98
44	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. Journal of Cardiac Failure, 2021, 27, 297-308.	0.7	4
45	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2021, 325, 39.	3.8	65
46	Generating evidence for therapeutic effects: the need for well-conducted randomized trials. Journal of Clinical Investigation, 2021, 131, .	3.9	6
47	Association of Severe Acute Kidney Injury with Mortality and Healthcare Utilization Following Isolated Traumatic Brain Injury. Neurocritical Care, 2021, 35, 434-440.	1.2	10
48	Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial. Trials, 2021, 22, 90.	0.7	9
49	Leveraging â€œBig Dataâ€œ for the Design and Execution of Clinical Trials. , 2021, , 1-23.		0
50	Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the <scp>EXSCEL</scp> and <scp>SAVORâ€œTIMI</scp> 53 cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2021, 23, 1101-1110.	2.2	4
51	Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors. Stroke and Vascular Neurology, 2021, 6, 384-394.	1.5	3
52	Data Sharing Goals for Nonprofit Funders of Clinical Trials. Journal of Participatory Medicine, 2021, 13, e23011.	0.7	2
53	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. Diabetic Medicine, 2021, 38, e14552.	1.2	5
54	Impact of the Early Phase of the COVID-19 Pandemic on US Healthcare Workers: Results from the HERO Registry. Journal of General Internal Medicine, 2021, 36, 1319-1326.	1.3	52

#	ARTICLE	IF	CITATIONS
55	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	1.6	24
56	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 293-300.	1.9	28
57	Association of Early Multiple Organ Dysfunction With Clinical and Functional Outcomes Over the Year Following Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study. <i>Critical Care Medicine</i> , 2021, 49, 1769-1778.	0.4	17
58	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2432-2447.	1.2	17
59	Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. <i>European Journal of Heart Failure</i> , 2021, 23, 1076-1084.	2.9	37
60	Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 522.	3.0	62
61	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1981-1990.	13.9	145
62	Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. <i>American Heart Journal</i> , 2021, 235, 82-96.	1.2	7
63	Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2670-2678.	1.4	7
64	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , 2021, 14, e008100.	1.6	30
65	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 336-345.	1.9	23
66	Multiparameter diagnostic sensor measurements in heart failure patients presenting with SARS-CoV-2 infection. <i>ESC Heart Failure</i> , 2021, 8, 4026-4036.	1.4	5
67	2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. <i>Circulation</i> , 2021, 143, e1035-e1087.	1.6	13
68	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Tj ETQq0 0 0 rg BT/Overlook 10 Tf 50		
69	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1217-1225.	2.9	195
70	Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 164.	1.0	9
71	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event. <i>JAMA Cardiology</i> , 2021, 6, 706.	3.0	53
72	Is Learning Worth the Trouble? Improving Health Care System Participation in Embedded Research. <i>New England Journal of Medicine</i> , 2021, 385, 5-7.	13.9	15

#	ARTICLE	IF	CITATIONS
73	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. ESC Heart Failure, 2021, 8, 2608-2616.	1.4	8
74	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. Journal of Cardiac Failure, 2021, 27, 670-676.	0.7	16
75	2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. Journal of the American College of Cardiology, 2021, 77, 3079-3133.	1.2	12
76	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e23-e106.	0.4	33
77	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. European Journal of Heart Failure, 2021, 23, 1300-1312.	2.9	35
78	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. JAMA Network Open, 2021, 4, e2117963.	2.8	5
79	Return of individual research results: What do participants prefer and expect?. PLoS ONE, 2021, 16, e0254153.	1.1	10
80	The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary Study. Trials, 2021, 22, 465.	0.7	10
81	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 314.	3.8	68
82	Transmethylamine Nitric Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV. Journal of the American Heart Association, 2021, 10, e020499.	1.6	7
83	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation, 2021, 144, 1489-1499.	1.6	21
84	Participation in a Heart Failure Clinical Trial. Circulation: Heart Failure, 2021, 14, e008242.	1.6	12
85	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e021459.	1.6	10
86	Clinical Outcome Predictions for the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. Journal of Cardiac Failure, 2021, 27, 949-956.	0.7	8
87	Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. American Heart Journal, 2021, 239, 110-119.	1.2	3
88	Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. American Heart Journal, 2021, 239, 59-63.	1.2	4
89	Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. JACC: Heart Failure, 2021, 9, 28-38.	1.9	43
90	Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circulation: Heart Failure, 2021, 14, e008351.	1.6	10

#	ARTICLE	IF	CITATIONS
91	Echocardiogram Utilization Patterns and Association With Mortality Following Severe Traumatic Brain Injury. <i>Anesthesia and Analgesia</i> , 2021, 132, 1060-1066.	1.1	1
92	Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. <i>Atherosclerosis</i> , 2021, 338, 1-6.	0.4	6
93	Impact of the COVID-19 Pandemic on Cardiovascular Science: Anticipating Problems and Potential Solutions: A Presidential Advisory From the American Heart Association. <i>Circulation</i> , 2021, 144, e461-e471.	1.6	11
94	Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021094.	1.6	23
95	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 918-932.	1.9	41
96	A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients With Heart Failure With Reduced Ejection Fraction—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1977.	3.8	0
97	Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, CIRCOUTCOMES121008190.	0.9	9
98	Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery—A Comprehensive Review of the Literature. <i>Biomolecules</i> , 2021, 11, 1870.	1.8	13
99	Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding. <i>European Stroke Journal</i> , 2020, 5, 47-55.	2.7	11
100	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , 2020, 220, 41-50.	1.2	22
101	Quality and Outcomes in Heart Failure. , 2020, , 697-704.e2.		0
102	Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 214-219.	1.0	6
103	Circulating Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 70-80.	1.9	21
104	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. <i>Journal of Cardiac Failure</i> , 2020, 26, 371-380.	0.7	25
105	The Hospital Readmissions Reduction Program. <i>JACC: Heart Failure</i> , 2020, 8, 1-11.	1.9	57
106	Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2020, 43, 374-381.	4.3	4
107	Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006031.	0.9	12
108	Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 798-806.	2.2	11



#	ARTICLE	IF	CITATIONS
109	Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines “Heart Failure Program). American Journal of Cardiology, 2020, 125, 894-900.	0.7	15
110	Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal of Cardiac Failure, 2020, 26, 270-275.	0.7	10
111	Hospital Factors Associated With Interhospital Transfer Destination for Stroke in the Northeast United States. Journal of the American Heart Association, 2020, 9, e011575.	1.6	18
112	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care, 2020, 43, 643-652.	4.3	38
113	Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. Contemporary Clinical Trials, 2020, 88, 105775.	0.8	5
114	Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?. American Heart Journal, 2020, 220, 97-107.	1.2	6
115	Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits After LVAD Placement?â€”A Call for a Randomized Clinical Trial. JAMA Cardiology, 2020, 5, 183.	3.0	1
116	Speckle Tracking Analysis of Left Ventricular Systolic Function Following Traumatic Brain Injury: A Pilot Prospective Observational Cohort Study. Journal of Neurosurgical Anesthesiology, 2020, 32, 156-161.	0.6	8
117	From Theory to Practice. JACC: Heart Failure, 2020, 8, 55-56.	1.9	1
118	Eligibility of sodium-glucose co-transporter <sup>2</sup> inhibitors among patients with diabetes mellitus admitted for heart failure. ESC Heart Failure, 2020, 7, 275-279.	1.4	6
119	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care, 2020, 43, 446-452.	4.3	63
120	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. JACC: Heart Failure, 2020, 8, 931-939.	1.9	88
121	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1512.	3.8	170
122	PROVIDE-HF primary results: Patient-Reported Outcomes in Investigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. American Heart Journal, 2020, 230, 35-43.	1.2	8
123	Disseminating trial results: We can have both faster and better. Healthcare, 2020, 8, 100474.	0.6	1
124	Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006606.	0.9	12
125	Considerations for using distributed research networks to conduct aspects of randomized trials. Contemporary Clinical Trials Communications, 2020, 17, 100515.	0.5	5
126	Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations. Journal of the American College of Cardiology, 2020, 76, 2878-2894.	1.2	68



#	ARTICLE	IF	CITATIONS
127	Expected vs Actual Outcomes of Elective Initiation of Inotropic Therapy During Heart Failure Hospitalization. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2020, 4, 529-536.	1.2	4
128	Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 625.	3.8	40
129	Heart Failure Clinical Trial Operations During the COVID-19 Pandemic. <i>Circulation: Heart Failure</i> , 2020, 13, e007456.	1.6	6
130	Randomized Trials Versus Common Sense and Clinical Observation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 580-589.	1.2	50
131	The Use of Sacubitril/Valsartan for Hospitalized Heart Failure—Why Do We Care About Cost and Value?. <i>JAMA Cardiology</i> , 2020, 5, 1244.	3.0	1
132	National Hospital Quality Rankings. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 839.	3.8	14
133	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. <i>Circulation</i> , 2020, 142, 1205-1218.	1.6	63
134	Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials. <i>Statistics in Medicine</i> , 2020, 39, 4218-4237.	0.8	18
135	Improving Care for Patients after Hospitalization with AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2237-2241.	3.0	24
136	Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy. <i>Journal of Cardiac Failure</i> , 2020, 26, 1108-1109.	0.7	0
137	Association Between Switching to a High-Deductible Health Plan and Major Cardiovascular Outcomes. <i>JAMA Network Open</i> , 2020, 3, e208939.	2.8	15
138	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	1.6	8
139	Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e012405.	1.6	2
140	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 789-799.	1.9	39
141	Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1477-1488.	0.8	11
142	The Project Baseline Health Study: a step towards a broader mission to map human health. <i>Npj Digital Medicine</i> , 2020, 3, 84.	5.7	38
143	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65
144	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. <i>American Heart Journal</i> , 2020, 226, 13-23.	1.2	7

#	ARTICLE	IF	CITATIONS
145	Splanchnic Nerve Block for Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 742-752.	1.9	44
146	Generating comparative evidence on new drugs and devices after approval. <i>Lancet</i> , 2020, 395, 998-1010.	6.3	52
147	The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. <i>CJC Open</i> , 2020, 2, 151-160.	0.7	10
148	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCCEL Outcomes. <i>Circulation</i> , 2020, 141, 1360-1370.	1.6	9
149	Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006963.	1.6	13
150	Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. <i>JAMA Cardiology</i> , 2020, 5, 598.	3.0	59
151	Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 643-651.	3.0	7
152	The burden of noncardiac comorbidities and association with clinical outcomes in an acute heart failure trial—Insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	2.9	27
153	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	13.9	753
154	Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006833.	1.6	25
155	Prospective and External Evaluation of a Machine Learning Model to Predict In-Hospital Mortality of Adults at Time of Admission. <i>JAMA Network Open</i> , 2020, 3, e1920733.	2.8	78
156	Machine learning to predict venous thrombosis in acutely ill medical patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 230-237.	1.0	28
157	Predischarge initiation of Ivabradine in the Management of Heart Failure: Results of the PRIME-HF Trial. <i>American Heart Journal</i> , 2020, 223, 98-105.	1.2	12
158	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	2.9	33
159	Association of Implantable Device Measured Physical Activity With Hospitalization for Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 280-288.	1.9	15
160	A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 540-548.	1.1	5
161	Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 233-242.	0.7	9
162	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 159-169.	0.8	89

#	ARTICLE	IF	CITATIONS
163	Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. <i>JAMA Cardiology</i> , 2020, 5, 986.	3.0	29
164	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). <i>American Journal of Cardiology</i> , 2020, 125, 1655-1660.	0.7	7
165	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. <i>American Journal of Cardiology</i> , 2020, 126, 94-102.	0.7	25
166	Evidence from Pragmatic Trials during Routine Care “Slouching toward a Learning Health System. <i>New England Journal of Medicine</i> , 2020, 382, 1488-1491.	13.9	35
167	Time for NIH to lead on data sharing. <i>Science</i> , 2020, 367, 1308-1309.	6.0	42
168	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006645.	1.6	18
169	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF. <i>JACC: Heart Failure</i> , 2020, 8, 469-480.	1.9	47
170	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. <i>Journal of the American Heart Association</i> , 2020, 9, e015752.	1.6	11
171	Abstract 13829: Index Event, Clinical Outcomes and Response to Vericiguat in the Victoria Trial. <i>Circulation</i> , 2020, 142, .	1.6	0
172	Abstract 17114: Whose Work is It? Patient Perspectives on Challenges in Heart Failure Self-Management. <i>Circulation</i> , 2020, 142, .	1.6	0
173	Abstract 12817: Comparison of New York Heart Association Classification and Patient-reported Outcomes Among Heart Failure Patients in U.S. Clinical Practice: CHAMP-HF. <i>Circulation</i> , 2020, 142, .	1.6	0
174	Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. <i>Clinical Cardiology</i> , 2019, 42, 256-263.	0.7	9
175	Net clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2089-2098.	1.9	5
176	Intravenous Tissue Plasminogen Activator in Stroke Mimics. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005609.	0.9	37
177	Evolving the Hospital Readmissions Reduction Program. <i>Journal of the American College of Cardiology</i> , 2019, 74, 235-237.	1.2	2
178	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. <i>JAMA Neurology</i> , 2019, 76, 1192.	4.5	70
179	Recent Myocardial Infarction is Associated With Increased Risk in Older Adults With Acute Ischemic Stroke Receiving Thrombolytic Therapy. <i>Journal of the American Heart Association</i> , 2019, 8, e012450.	1.6	11
180	Representativeness of a Heart Failure Trial by Race and Sex. <i>JACC: Heart Failure</i> , 2019, 7, 980-992.	1.9	30

#	ARTICLE	IF	CITATIONS
181	PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 1009-1011.	0.7	5
182	Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988000.	0.7	7
183	Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review. <i>PLoS ONE</i> , 2019, 14, e0219894.	1.1	10
184	Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). <i>American Journal of Cardiology</i> , 2019, 124, 1900-1906.	0.7	19
185	Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1426-1433.	2.9	27
186	The Future of Wearables in Heart Failure Patients. <i>JACC: Heart Failure</i> , 2019, 7, 922-932.	1.9	101
187	Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. <i>Circulation: Heart Failure</i> , 2019, 12, e005171.	1.6	15
188	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 138.	2.7	48
189	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1472-1476.	2.9	2
190	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, S151.	0.7	0
191	Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2019, 140, 1115-1124.	1.6	33
192	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes. <i>Circulation</i> , 2019, 140, 1613-1622.	1.6	58
193	Hospital-based quality improvement interventions for patients with heart failure: a systematic review. <i>Heart</i> , 2019, 105, 431-438.	1.2	11
194	Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry. <i>American Heart Journal</i> , 2019, 211, 1-10.	1.2	17
195	Heart Failure With Preserved Ejection Fraction and Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 602-611.	1.2	182
196	Relationship Between Hospital Characteristics and Early Adoption of Angiotensin Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. <i>Journal of the American Heart Association</i> , 2019, 8, e010484.	1.6	13
197	The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2019, 124, 545-553.	0.7	29
198	Association of Changes in Heart Failure Treatment With Patients' Health Status. <i>JACC: Heart Failure</i> , 2019, 7, 615-625.	1.9	20

#	ARTICLE	IF	CITATIONS
199	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019, 12, e005998.	1.6	33
200	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2365-2383.	1.2	327
201	Addressing guideline and policy changes during pragmatic clinical trials. <i>Clinical Trials</i> , 2019, 16, 431-437.	0.7	7
202	The Association of Black Cardiologists (ABC) Cardiovascular Implementation Study (CVIS): A Research Registry Integrating Social Determinants to Support Care for Underserved Patients. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1631.	1.2	6
203	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019, 03, e103-e108.	0.7	1
204	OUTCOMES OF NON-SURGICAL PATIENTS WITH SEVERE TRICUSPID REGURGITATION AND CONGESTIVE HEART FAILURE. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1948.	1.2	3
205	PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCEL TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2040.	1.2	1
206	Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus. <i>Stroke</i> , 2019, 50, 1497-1503.	1.0	10
207	Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2019, 42, 1075-1080.	4.3	15
208	PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. <i>Journal of the American Heart Association</i> , 2019, 8, e011246.	1.6	44
209	Heart failure drug treatment. <i>Lancet, The</i> , 2019, 393, 1034-1044.	6.3	233
210	Trends in Readmissions and Length of Stay for Patients Hospitalized With Heart Failure in Canada and the United States. <i>JAMA Cardiology</i> , 2019, 4, 444.	3.0	75
211	Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance. <i>Clinical Trials</i> , 2019, 16, 290-296.	0.7	7
212	Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. <i>American Heart Journal</i> , 2019, 212, 101-112.	1.2	18
213	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, 703-711.	0.7	11
214	Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1097-1105.	0.8	19
215	Target Doses of Heart Failure Medical Therapy and Blood Pressure. <i>JACC: Heart Failure</i> , 2019, 7, 350-358.	1.9	67
216	Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. <i>Circulation</i> , 2019, 139, 1234-1236.	1.6	7

#	ARTICLE	IF	CITATIONS
217	What Is Needed Now to Improve Cardiovascular Clinical Registries in the Future. <i>JAMA Cardiology</i> , 2019, 4, 201.	3.0	0
218	Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. <i>Intensive Care Medicine</i> , 2019, 45, 477-487.	3.9	17
219	Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 223-225.	0.6	15
220	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008018.	1.4	25
221	Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018. <i>PLoS ONE</i> , 2019, 14, e0223515.	1.1	6
222	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 2108-2118.	1.6	22
223	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.95	65
224	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart Failure. <i>Journal of the American Heart Association</i> , 2019, 8, e011560.	1.6	68
225	Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). <i>American Journal of Cardiology</i> , 2019, 123, 618-626.	0.7	5
226	Ischemic Stroke Transfer Patterns in the Northeast United States. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 295-304.	0.7	10
227	Reply. <i>JACC: Heart Failure</i> , 2019, 7, 85.	1.9	0
228	Statistical Code for Clinical Research Papers. <i>Annals of Internal Medicine</i> , 2019, 170, 80.	2.0	0
229	High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 177-186.	1.2	37
230	History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 47-55.	1.9	10
231	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. <i>Diabetes Care</i> , 2019, 42, 318-326.	4.3	23
232	Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. <i>American Journal of Hematology</i> , 2019, 94, 21-28.	2.0	50
233	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. <i>Journal of Cardiac Failure</i> , 2018, 24, 255-265.	0.7	32
234	Intra-Aortic Balloon Pump Use Before Left Ventricular Assist Device Implantation: Insights From the INTERMACS Registry. <i>ASAIO Journal</i> , 2018, 64, 218-224.	0.9	13



#	ARTICLE	IF	CITATIONS
235	Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. <i>Clinical Cardiology</i> , 2018, 41, 758-768.	0.7	43
236	Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018, 24, 428-438.	0.7	31
237	Interaction of Body Mass Index on the Association Between N-Terminal Pro-B-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study) Type Natriuretic Peptide and Association. 2018, 7, .	1.6	12
238	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. <i>American Journal of Medicine</i> , 2018, 131, 972.e1-972.e7.	0.6	29
239	Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions. <i>Circulation: Heart Failure</i> , 2018, 11, e004634.	1.6	20
240	Health Status Variation Across Practices in Outpatients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004668.	0.9	15
241	Timing of Postdischarge Follow-up and Medication Adherence Among Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	13
242	Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 388-397.	1.9	21
243	Absence of July Phenomenon in Acute Ischemic Stroke Care Quality and Outcomes. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	3
244	Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 463.	3.8	180
245	Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure. <i>Circulation</i> , 2018, 137, 1661-1670.	1.6	46
246	Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke. <i>European Heart Journal</i> , 2018, 39, 2376-2386.	1.0	62
247	Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2018, 200, 134-140.	1.2	8
248	Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. <i>Circulation</i> , 2018, 137, 2016-2028.	1.6	239
249	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients. <i>Circulation</i> , 2018, 137, 91-94.	1.6	27
250	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 525-532.	2.9	29
251	Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry. <i>American Heart Journal</i> , 2018, 198, 123-128.	1.2	10
252	Rationale and design of the comparison of sacubitril/valsartan versus Enalapril on Effect on natriuretic peptide receptor-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. <i>American Heart Journal</i> , 2018, 198, 145-151.	1.2	60



#	ARTICLE	IF	CITATIONS
253	A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. <i>American Heart Journal</i> , 2018, 200, 127-133.	1.2	13
254	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , 2018, 198, 84-90.	1.2	19
255	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 105-113.	5.5	451
256	Trends and outcomes of cardiac transplantation from donors dying of drug intoxication. <i>American Heart Journal</i> , 2018, 199, 92-96.	1.2	10
257	Leveraging electronic health records for clinical research. <i>American Heart Journal</i> , 2018, 202, 13-19.	1.2	36
258	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 298-307.	1.9	4
259	Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	16
260	Paving a Better Path for Patients Dying of Heart Disease. <i>Circulation</i> , 2018, 137, 1216-1217.	1.6	5
261	Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization. <i>JAMA Cardiology</i> , 2018, 3, 489.	3.0	37
262	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. <i>JACC: Heart Failure</i> , 2018, 6, 96-104.	1.9	141
263	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 1-8.	1.0	14
264	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 304-314.	2.9	42
265	Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors. <i>American Journal of Transplantation</i> , 2018, 18, 1461-1470.	2.6	108
266	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. <i>JAMA Cardiology</i> , 2018, 3, 44.	3.0	346
267	Assessing Frailty in Patients Undergoing Destination Therapy Left Ventricular Assist Device: Observations from Interagency Registry for Mechanically Assisted Circulatory Support. <i>ASAIO Journal</i> , 2018, 64, 16-23.	0.9	33
268	Periprocedural Risk and Survival after ICD Placement in Patients with Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2018, 24, S63.	0.7	0
269	Improvements in Health Status Associated with Medication Adjustments in Outpatients with HFrEF: Insights from the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2018, 24, S102-S103.	0.7	0
270	Response by Kumbhani et al to Letters Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure". <i>Circulation</i> , 2018, 138, 2306-2307.	1.6	2

#	ARTICLE	IF	CITATIONS
271	Engaging patients throughout the health system: A landscape analysis of cold-call policies and recommendations for future policy change. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 384-392.	0.3	7
272	Diabetes is Associated with Worse In-Hospital and 30-Day Post-Discharge Morbidity in Patients with Heart Failure with Preserved Ejection Fraction: Findings from the Get With The Guidelines Heart Failure Registry. <i>Journal of Cardiac Failure</i> , 2018, 24, S92.	0.7	0
273	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2046-2052.	1.8	48
274	Association of Kidney Function With 30-Day and 1-Year Poststroke Mortality and Hospital Readmission. <i>Stroke</i> , 2018, 49, 2896-2903.	1.0	18
275	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1764.	3.8	187
276	High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. <i>Journal of the American Heart Association</i> , 2018, 7, e010364.	1.6	22
277	Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?. <i>Circulation</i> , 2018, 138, 2787-2797.	1.6	3
278	Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 2576-2578.	1.6	13
279	Providing Individual Research Results to Participants—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2601.	3.8	2
280	Association between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure with Reduced Ejection Fraction: Findings from the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2018, 24, S9.	0.7	0
281	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009304.	1.6	19
282	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , 2018, 392, 1519-1529.	6.3	1,179
283	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 512-519.	0.7	9
284	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	0.9	13
285	Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. <i>Circulation: Heart Failure</i> , 2018, 11, e005400.	1.6	36
286	Use of Target Doses of Guideline Directed Medical Therapy in Heart Failure by Systolic Blood Pressure: Insights from the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2018, 24, S71.	0.7	0
287	Patient and Practice Characteristics Associated with Sacubitril/Valsartan Use in the United States. <i>Journal of Cardiac Failure</i> , 2018, 24, S98-S99.	0.7	0
288	Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. <i>Stroke</i> , 2018, 49, 2237-2240.	1.0	25

#	ARTICLE	IF	CITATIONS
289	International Comparison of Patient Characteristics and Quality of Care for Ischemic Stroke: Analysis of the China National Stroke Registry and the American Heart Association Get With The Guidelinesâ€”Stroke Program. <i>Journal of the American Heart Association</i> , 2018, 7, e010623.	1.6	29
290	Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. <i>European Heart Journal</i> , 2018, 39, 4255-4256.	1.0	54
291	2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imagingâ€”Best Practices for Safety and Effectiveness, Part 1: Radiation Physics and Radiation Biology. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 203-221.	0.7	7
292	2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imagingâ€”Best Practices for Safety and Effectiveness, Part 2: Radiological Equipment Operation, Doseâ€”Sparing Methodologies, Patient and Medical Personnel Protection. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 222-246.	0.7	6
293	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1â€”receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1601-1610.	2.9	27
294	2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging: Best Practices for Safety and Effectiveness. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E35-E97.	0.7	12
295	Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelinesâ€”Heart Failure Registry. <i>JAMA Cardiology</i> , 2018, 3, 917.	3.0	50
296	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. <i>American Heart Journal</i> , 2018, 202, 97-103.	1.2	38
297	Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 465-473.	1.9	65
298	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCENDâ€”HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	0.7	22
299	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e004646.	1.6	134
300	Splanchnic Nerve Block for Acute Heart Failure. <i>Circulation</i> , 2018, 138, 951-953.	1.6	62
301	Association of the Affordable Care Actâ€™s Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004729.	0.9	31
302	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitusâ€”Rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2018, 203, 30-38.	1.2	51
303	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. <i>TH Open</i> , 2018, 02, e16-e24.	0.7	8
304	Review: In noncardiac surgery, amiodarone, $\beta$ -blocker, or statin prophylaxis reduces postoperative AF. <i>Annals of Internal Medicine</i> , 2018, 169, JC7.	2.0	0
305	Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 351-366.	1.2	775
306	Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the <sc>FIGHT</sc> trial. <i>ESC Heart Failure</i> , 2018, 5, 1035-1043.	1.4	25

#	ARTICLE	IF	CITATIONS
307	Vaccination Trends in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 844-855.	1.9	30
308	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16
309	The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. <i>Clinical Cardiology</i> , 2018, 41, 1259-1267.	0.7	10
310	The Call for Precision Health Trials in Older Adults. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2537-2539.	1.2	0
311	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2643-2652.	1.2	72
312	Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	26
313	Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy. <i>European Journal of Heart Failure</i> , 2018, 20, 1227-1229.	2.9	1
314	Return of Research Results to Study Participants. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 435.	3.8	49
315	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes</i> , 2018, 67, .	0.3	42
316	Relationship between Hospital 30-Day Mortality Rates for Heart Failure and Patterns of Early Inpatient Comfort Care. <i>Journal of Hospital Medicine</i> , 2018, 13, 170-176.	0.7	3
317	EXSCEL—Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus. <i>Diabetes</i> , 2018, 67, 1319-P.	0.3	0
318	Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group. <i>Diabetes</i> , 2018, 67, 130-LB.	0.3	0
319	Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	82
320	Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. <i>American Journal of Cardiology</i> , 2017, 119, 886-892.	0.7	9
321	Can Vaccinations Improve Heart Failure Outcomes?. <i>JACC: Heart Failure</i> , 2017, 5, 194-203.	1.9	47
322	Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	18
323	Impact of an Expanded Hospital Recognition Program for Stroke Quality of Care. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	7
324	Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. <i>Circulation</i> , 2017, 135, 1024-1035.	1.6	48

#	ARTICLE	IF	CITATIONS
325	Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the <sc>RELAX</sc> trial. European Journal of Heart Failure, 2017, 19, 893-900.	2.9	123
326	Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program" Circulation, 2017, 135, e22-e23.	1.6	2
327	Acute Heart Failure. JACC: Heart Failure, 2017, 5, 329-336.	1.9	29
328	Healthcare Resource Availability, Quality of Care, and Acute Ischemic Stroke Outcomes. Journal of the American Heart Association, 2017, 6, .	1.6	17
329	Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	1.6	104
330	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI "Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	2.5	59
331	When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. American Heart Journal, 2017, 189, 1-8.	1.2	14
332	Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. American Heart Journal, 2017, 188, 127-135.	1.2	5
333	Engagement, Research, and Evidence. Circulation, 2017, 135, 1478-1480.	1.6	5
334	Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelines "Coronary Artery Disease (GWTG-CAD) program. American Heart Journal, 2017, 189, 85-93.	1.2	58
335	Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients. American Heart Journal, 2017, 189, 146-157.	1.2	15
336	Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. American Heart Journal, 2017, 189, 177-183.	1.2	43
337	Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency. JAMA - Journal of the American Medical Association, 2017, 317, 1958.	3.8	329
338	INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	47
339	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the) Tj ETQq1 1 0,784314 rgBT /Overl	0,7	15
340	Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2017, 2, 896.	3.0	31
341	Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. JACC: Heart Failure, 2017, 5, 388-392.	1.9	11
342	Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. American Heart Journal, 2017, 189, 48-58.	1.2	29

#	ARTICLE	IF	CITATIONS
343	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 483-493.	1.9	41
344	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039.	1.2	69
345	Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, e003878.	1.6	45
346	Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization. <i>Circulation</i> , 2017, 135, 2077-2080.	1.6	28
347	An Initial Evaluation of the Impact of Pokémon GO on Physical Activity. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	54
348	TIMING AND CLINICAL PREDICTORS OF EARLY VERSUS LATE READMISSION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 766.	1.2	2
349	HEMOCONCENTRATION DURING MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE AND CARDIORENAL SYNDROME: INSIGHTS FROM CARRESS-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 767.	1.2	0
350	THE IMPACT OF THE CURRENT VERSUS PRIOR CARDIAC RESYNCHRONIZATION GUIDELINES ON THE PROPORTION OF HOSPITALIZED HEART FAILURE PATIENTS ELIGIBLE FOR THERAPY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 784.	1.2	0
351	A HOSPITAL LEVEL ANALYSIS OF 30-DAY READMISSION RATES FOR HEART FAILURE PATIENTS AND LONG-TERM SURVIVAL AMONG HIGHEST AND LOWEST PERFORMING HOSPITALS, FINDINGS FROM GET WITH THE GUIDELINES-HEART FAILURE. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2565.	1.2	0
352	ASSOCIATION BETWEEN SERUM POTASSIUM LEVEL AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A COHORT STUDY FROM THE SWEDISH HEART FAILURE REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 678.	1.2	3
353	Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 305-309.	1.9	101
354	Integrating Research With Clinical Practice. <i>JAMA Cardiology</i> , 2017, 2, 616.	3.0	0
355	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017, 187, 1-9.	1.2	49
356	Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1057.	3.8	179
357	Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 136.	3.0	50
358	Renal Dysfunction Is Associated With Poststroke Discharge Disposition and In-Hospital Mortality. <i>Stroke</i> , 2017, 48, 327-334.	1.0	58
359	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Treatment Trial. <i>Journal of the American College of Cardiology</i> , 2017, 185, 93-100.	1.2	48
360	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	1.9	84



#	ARTICLE	IF	CITATIONS
361	Making Every Mobile Heart Count!. JAMA Cardiology, 2017, 2, 78.	3.0	0
362	The Burden of Non-Cardiac Comorbidities in Acute Heart Failure: Insights From ASCEND-HF. Journal of Cardiac Failure, 2017, 23, S109.	0.7	0
363	When Should Patients Be Involved in Cardiovascular Clinical Trial Design?. JAMA Cardiology, 2017, 2, 1269.	3.0	3
364	Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. Pharmaceutical Statistics, 2017, 16, 445-450.	0.7	8
365	Leveraging Behavioral Economics to Improve Heart Failure Care and Outcomes. Circulation, 2017, 136, 765-772.	1.6	27
366	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. Journal of Thrombosis and Thrombolysis, 2017, 44, 457-465.	1.0	11
367	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 1228-1239.	13.9	1,455
368	Role of Volume Redistribution in the Congestion of Heart Failure. Journal of the American Heart Association, 2017, 6, .	1.6	128
369	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology, 2017, 33, 1342-1433.	0.8	503
370	Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Journal of the American Heart Association, 2017, 6, .	1.6	40
371	Improving heart failure health: is there a secret Swedish sauce?. European Journal of Heart Failure, 2017, 19, 1117-1118.	2.9	0
372	Representativeness of Medicare Participants in the Jackson Heart Study for African American Medicare Beneficiaries. Epidemiology, 2017, 28, 740-746.	1.2	1
373	Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. Journal of Thrombosis and Haemostasis, 2017, 15, 1913-1922.	1.9	20
374	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open, 2017, 01, e56-e65.	0.7	94
375	Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2017, 70, 2476-2486.	1.2	671
376	Efficacy and Safety of Spironolactone in Acute Heart Failure. JAMA Cardiology, 2017, 2, 950.	3.0	199
377	Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population. Circulation, 2017, 135, 128-139.	1.6	129
378	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. Circulation, 2017, 135, 648-655.	1.6	61



#	ARTICLE	IF	CITATIONS
379	Sex and Age Interactions and Differences in Outcomes After Intracerebral Hemorrhage. <i>Journal of Women's Health</i> , 2017, 26, 380-388.	1.5	17
380	Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 204.	3.0	249
381	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. <i>Clinical Cardiology</i> , 2017, 40, 38-45.	0.7	13
382	Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 202-210.	0.3	49
383	Resting Heart Rate and Long-term Outcomes Among the African American Population. <i>JAMA Cardiology</i> , 2017, 2, 172.	3.0	23
384	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 241-249.	2.9	22
385	Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 2502-2502.	13.9	10
386	Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2389-2395.	1.8	22
387	Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	32
388	How Medicine Has Changed the End of Life for Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1276-1289.	1.2	52
389	Data Sharing and Embedded Research. <i>Annals of Internal Medicine</i> , 2017, 167, 668.	2.0	18
390	Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory. <i>BMC Medical Research Methodology</i> , 2017, 17, 144.	1.4	127
391	Trends in the Care and Outcomes of Medicare Beneficiaries with Type 2 Diabetes, 2002-2011. <i>Endocrine Practice</i> , 2016, 22, 920-934.	1.1	9
392	Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women": <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	0
393	Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization. <i>Medical Care</i> , 2016, 54, 365-372.	1.1	89
394	Assessment of Home-Time After Acute Ischemic Stroke in Medicare Beneficiaries. <i>Stroke</i> , 2016, 47, 836-842.	1.0	67
395	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	2.9	36
396	Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 424-432.	2.9	45

#	ARTICLE	IF	CITATIONS
397	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. <i>European Journal of Heart Failure</i> , 2016, 18, 684-692.	2.9	14
398	Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 935-946.	1.9	68
399	Pulmonary Hypertension in the Era of Mechanical Circulatory Support. <i>ASAIO Journal</i> , 2016, 62, 505-512.	0.9	17
400	Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	5
401	Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 781-788.	0.7	24
402	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, 534-544.	13.9	379
403	Association of Get With The Guidelines-Stroke Program Participation and Clinical Outcomes for Medicare Beneficiaries With Ischemic Stroke. <i>Stroke</i> , 2016, 47, 1294-1302.	1.0	52
404	Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	38
405	Finerenone in heart failure: walking a fine line. <i>European Heart Journal</i> , 2016, 37, 2115-2117.	1.0	9
406	Heart failure medications prescribed at discharge for patients with left ventricular assist devices. <i>American Heart Journal</i> , 2016, 179, 99-106.	1.2	8
407	Insufficient Reduction in Heart Rate during Hospitalization Despite Beta-Blocker Treatment in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, S100-S101.	0.7	0
408	Laboratory Monitoring after Inpatient and Outpatient Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients with Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, S26.	0.7	0
409	Regional Differences during Acute Heart Failure Hospitalizations of Patients with Heart Failure with Preserved Ejection Fraction: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2016, 22, S27.	0.7	0
410	Response to Letter Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure." <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	0
411	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	15
412	Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. <i>American Heart Journal</i> , 2016, 182, 28-35.	1.2	12
413	Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	178
414	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 500.	3.8	457

#	ARTICLE	IF	CITATIONS
415	Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). <i>American Heart Journal</i> , 2016, 178, 198-205.	1.2	14
416	The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2016, 18, 81.	1.3	54
417	Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure. <i>Circulation</i> , 2016, 134, 517-526.	1.6	90
418	Rationale and Design of the ATHENA-HF Trial. <i>JACC: Heart Failure</i> , 2016, 4, 726-735.	1.9	30
419	Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. <i>European Journal of Heart Failure</i> , 2016, 18, 290-297.	2.9	47
420	The Potential Impact of Expanding Cardiac Rehabilitation in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 977-978.	1.2	6
421	Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	127
422	Hospital Variation in Home-Time After Acute Ischemic Stroke. <i>Stroke</i> , 2016, 47, 2627-2633.	1.0	33
423	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. <i>American Heart Journal</i> , 2016, 182, 9-20.	1.2	115
424	Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. <i>European Journal of Heart Failure</i> , 2016, 18, 1238-1243.	2.9	56
425	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	19
426	The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1898-1907.	1.2	75
427	Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 757-766.	0.9	22
428	Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG-CAD) Registry. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	16
429	Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>BMJ Open</i> , 2016, 6, e010201.	0.8	11
430	Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. <i>JAMA Cardiology</i> , 2016, 1, 714.	3.0	89
431	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq1 1 0.784314 rgBT /Overlo 0.7 26	0.7	26
432	The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study. <i>Journal of Cardiac Failure</i> , 2016, 22, 589-597.	0.7	19

#	ARTICLE	IF	CITATIONS
433	Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 464-472.	1.9	179
434	Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 649-661.	1.9	16
435	Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	13
436	Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. <i>American Journal of Cardiology</i> , 2016, 117, 946-951.	0.7	23
437	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCCEL) trial. <i>American Heart Journal</i> , 2016, 174, 103-110.	1.2	82
438	Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 68-77.	1.9	45
439	Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. <i>Journal of Cardiac Failure</i> , 2016, 22, 738-742.	0.7	23
440	Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. <i>JAMA Neurology</i> , 2016, 73, 50.	4.5	54
441	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016, 117, 404-411.	0.7	47
442	Evaluation of a provocative dyspnea severity score in acute heart failure. <i>American Heart Journal</i> , 2016, 172, 34-41.	1.2	9
443	Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2016, 22, 409-416.	0.7	9
444	Utility of Patient-Reported Outcome Instruments in Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 165-175.	1.9	120
445	Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 348-356.	1.9	38
446	Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS. <i>Journal of Cardiac Failure</i> , 2016, 22, 672-679.	0.7	34
447	Trends and outcomes of patients with adult congenital heart disease and pulmonary hypertension listed for orthotopic heart transplantation in the United States. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 619-624.	0.3	27
448	Has Public Reporting of Hospital Readmission Rates Affected Patient Outcomes?. <i>Journal of the American College of Cardiology</i> , 2016, 67, 963-972.	1.2	46
449	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. <i>Circulation: Heart Failure</i> , 2016, 9, e002630.	1.6	28
450	Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	24

#	ARTICLE	IF	CITATIONS
451	Clinical Effectiveness of Hydralazine+Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. <i>Circulation: Heart Failure</i> , 2016, 9, e002444.	1.6	29
452	Sex and Race/Ethnicity-Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, S36-44.	0.9	57
453	Good Clinical Practice Guidance and Pragmatic Clinical Trials. <i>Circulation</i> , 2016, 133, 872-880.	1.6	79
454	Discharge heart rate and $\beta$ -blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. <i>American Heart Journal</i> , 2016, 173, 172-178.	1.2	28
455	Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease. <i>American Heart Journal</i> , 2016, 173, 27-34.	1.2	17
456	Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. <i>Journal of Cardiac Failure</i> , 2016, 22, 853-858.	0.7	7
457	Association of Arterial Pulse Pressure With Long-Term Clinical Outcomes in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 42-49.	1.9	30
458	Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 362-369.	0.3	36
459	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 227-232.	1.0	9
460	Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 26-32.	0.7	48
461	Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy. <i>PLoS ONE</i> , 2016, 11, e0164914.	1.1	12
462	The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Trial. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 16, 3824-3824.	0.6	0
463	Cardiac Transplantation for Older Patients: Characteristics and Outcomes in the Septuagenarian Population. <i>Journal of Cardiac Failure</i> , 2015, 21, S9.	0.7	0
464	Novel Protein Glycan Inflammatory Biomarkers Predict Adverse Events in Heart Failure with Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2015, 21, S89.	0.7	1
465	Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2015, 21, S120-S121.	0.7	0
466	Sex Differences in the Management and Outcomes of Heart Failure with Preserved Ejection Fraction in Patients Presenting to the Emergency Department with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, S62.	0.7	1
467	Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. <i>American Heart Journal</i> , 2015, 170, 1124-1132.	1.2	8
468	Temporal Trends of Digoxin Use in Patients Hospitalized with Heart Failure: Analysis From the American Heart Association Get With The Guidelines - Heart Failure Registry. <i>Journal of Cardiac Failure</i> , 2015, 21, S62.	0.7	0

#	ARTICLE	IF	CITATIONS
469	The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm. <i>Annals of Internal Medicine</i> , 2015, 163, 635-636.	2.0	91
470	Elevated Heart Rate in Patients with Heart Failure with Reduced Ejection Fraction: Associations with One-Year Survival and Costs. <i>Journal of Cardiac Failure</i> , 2015, 21, S121-S122.	0.7	2
471	Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. <i>Hepatology</i> , 2015, 62, 409-416.	3.6	58
472	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2015, 170, 298-305.	1.2	38
473	Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?. <i>JACC: Heart Failure</i> , 2015, 3, 497-504.	1.9	17
474	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 741-748.	1.6	235
475	Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2618-2629.	1.2	26
476	Ventricular Conduction and Long-Term Heart Failure Outcomes and Mortality in African Americans. <i>Circulation: Heart Failure</i> , 2015, 8, 243-251.	1.6	20
477	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. <i>Journal of the American Heart Association</i> , 2015, 4, e002061.	1.6	14
478	Depressive Symptoms and Risk of Cardiovascular Events in Blacks. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 552-559.	0.9	36
479	Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. <i>BMJ, The</i> , 2015, 351, h3786.	3.0	54
480	Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow. <i>American Journal of Cardiology</i> , 2015, 116, 573-579.	0.7	17
481	Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e002092.	1.6	25
482	Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function. <i>JACC: Heart Failure</i> , 2015, 3, 40-49.	1.9	35
483	Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 97-107.	1.9	95
484	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. <i>JACC: Heart Failure</i> , 2015, 3, 159-167.	1.9	30
485	Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction Trial. <i>Circulation: Heart Failure</i> , 2015, 8, 221-228.	1.6	31
486	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2015, 17, 340-346.	2.9	22



#	ARTICLE	IF	CITATIONS
487	Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, Fluid Homeostasis, Inflammation, and Renal Injury. <i>JACC: Heart Failure</i> , 2015, 3, 30-39.	1.9	70
488	Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial. <i>International Journal of Cardiology</i> , 2015, 182, 184-186.	0.8	2
489	Trends in Endovascular Therapy and Clinical Outcomes Within the Nationwide Get With The Guidelines-Stroke Registry. <i>Stroke</i> , 2015, 46, 989-995.	1.0	62
490	Transitions of Care in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 384-409.	1.6	206
491	Pooled RCTs: $\beta$ -blockers reduce mortality in heart failure patients with sinus rhythm but not in those with AF. <i>Annals of Internal Medicine</i> , 2015, 162, JC7.	2.0	1
492	Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. <i>Circulation</i> , 2015, 132, 1404-1413.	1.6	43
493	The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015, 169, 743-750.	1.2	15
494	Trends and Outcomes of Patients with Adult Congenital Heart Disease With Pulmonary Hypertension Listed for Orthotopic Heart Transplantation in the United Network for Organ Sharing Database. <i>Journal of Cardiac Failure</i> , 2015, 21, S8.	0.7	0
495	The Clinical Implications of Cardiac Troponin I Measured by an “Ultrasensitive” Assay in Acute Decompensated Heart Failure: Insights from ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2015, 21, S25-S26.	0.7	0
496	Trends in the Use of Guideline-based Therapies Among Dialysis Patients Hospitalized with Heart Failure: Findings from Get With The Guidelines-Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, S114-S115.	0.7	0
497	Lack of Impact of Electronic Health Records on Quality of Care and Outcomes for Ischemic Stroke. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1964-1972.	1.2	18
498	Measuring heart failure quality: does perfection matter?. <i>Heart</i> , 2015, 101, 1691-1692.	1.2	0
499	Characteristics, quality of care, and in-hospital outcomes of Asian-American heart failure patients: Findings from the American Heart Association Get With The Guidelines-Heart Failure Program. <i>International Journal of Cardiology</i> , 2015, 189, 141-147.	0.8	4
500	Assessing the Quality and Comparative Effectiveness of Team-Based Care for Heart Failure. <i>Heart Failure Clinics</i> , 2015, 11, 499-506.	1.0	28
501	Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 421-427.	0.9	22
502	Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 383-392.	0.9	52
503	Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	60
504	Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care. <i>American Heart Journal</i> , 2015, 170, 36-45.e11.	1.2	49



#	ARTICLE	IF	CITATIONS
505	Same-Day Discharge and Risks of Mortality and Readmission After Elective ICD Placement for Primary Prevention. <i>Journal of the American College of Cardiology</i> , 2015, 65, 955-957.	1.2	11
506	Results of the Chronic Heart Failure Intervention to Improve MEducation Adherence study: A randomized intervention in high-risk patients. <i>American Heart Journal</i> , 2015, 169, 539-548.	1.2	45
507	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. <i>Circulation</i> , 2015, 131, 1763-1771.	1.6	239
508	Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , 2015, 21, 519-534.	0.7	283
509	Diuretic response in acute heart failure—an analysis from ASCEND-HF. <i>American Heart Journal</i> , 2015, 170, 313-321.e4.	1.2	110
510	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015, 170, 290-297.e1.	1.2	57
511	Quality of Care and Ischemic Stroke Risk After Hospitalization for Transient Ischemic Attack. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S117-S124.	0.9	15
512	Smoking Paradox in Patients Hospitalized With Coronary Artery Disease or Acute Ischemic Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S73-80.	0.9	28
513	Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1973.	3.8	53
514	Utility of Socioeconomic Status in Predicting 30-Day Outcomes After Heart Failure Hospitalization. <i>Circulation: Heart Failure</i> , 2015, 8, 473-480.	1.6	55
515	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2015, 21, 674-693.	0.7	39
516	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 777-785.	1.9	19
517	Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. <i>JACC: Heart Failure</i> , 2015, 3, 906-916.	1.9	54
518	Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. <i>Circulation</i> , 2015, 132, 1347-1353.	1.6	81
519	Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 66, 917-926.	1.2	142
520	What's Harder: Seeing a Doctor or Reducing Readmissions? —. <i>JACC: Heart Failure</i> , 2015, 3, 774-776.	1.9	0
521	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. <i>American Journal of Medicine</i> , 2015, 128, 426.e1-426.e9.	0.6	31
522	Relation of Dyspnea Severity on Admission for Acute Heart Failure With Outcomes and Costs. <i>American Journal of Cardiology</i> , 2015, 115, 75-81.	0.7	35

#	ARTICLE	IF	CITATIONS
523	Recognition of biomarker identified high-risk patients in the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban study resulting in a protocol amendment. <i>American Heart Journal</i> , 2015, 169, 186-187.	1.2	9
524	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PProject of Ex-vivo Vein graft ENgineering via Transfection IV Trial. <i>American Heart Journal</i> , 2015, 169, 175-184.	1.2	23
525	QEEG Spectral and Coherence Assessment of Autistic Children in Three Different Experimental Conditions. <i>Journal of Autism and Developmental Disorders</i> , 2015, 45, 406-424.	1.7	54
526	d-Dimer elevation and adverse outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 55-59.	1.0	75
527	Implementation of Management Strategies for Diabetes and Hypertension: From Local to Global Health in Cardiovascular Diseases. <i>Global Heart</i> , 2015, 10, 31.	0.9	12
528	Epinephrine Activation of the $\beta_2$ -Adrenoceptor Is Required for IL-13-Induced Mucin Production in Human Bronchial Epithelial Cells. <i>PLoS ONE</i> , 2015, 10, e0132559.	1.1	14
529	Abstract 17368: Years of Life Lost Due to Heart Failure in the United States (US). <i>Circulation</i> , 2015, 132, .	1.6	1
530	Abstract 17304: Sudden Cardiac Death After Acute Heart Failure Hospitalization: Insights From ASCEND-HF. <i>Circulation</i> , 2015, 132, .	1.6	0
531	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. <i>Circulation: Heart Failure</i> , 2014, 7, 918-925.	1.6	42
532	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. <i>Circulation</i> , 2014, 130, 958-965.	1.6	41
533	Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure. <i>Evidence-Based Medicine</i> , 2014, 19, 153-153.	0.6	1
534	Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 123-130.	1.6	134
535	Valvular Heart Disease in Patients Supported With Left Ventricular Assist Devices. <i>Circulation: Heart Failure</i> , 2014, 7, 215-222.	1.6	60
536	In-Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	48
537	Clinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 926-934.	1.6	20
538	Quality of Care for Patients With Acute Coronary Syndromes as a Function of Hospital Revascularization Capability: Insights From Get With The Guidelines-CAD. <i>Clinical Cardiology</i> , 2014, 37, 285-292.	0.7	16
539	Transient and persistent worsening renal function during hospitalization for acute heart failure. <i>American Heart Journal</i> , 2014, 168, 891-900.	1.2	36
540	The association between meteorological events and acute heart failure: New insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 819-824.	0.8	9

#	ARTICLE	IF	CITATIONS
541	Management of Postoperative Atrial Fibrillation and Subsequent Outcomes in Contemporary Patients Undergoing Cardiac Surgery: Insights From the Society of Thoracic Surgeons <scp>CAPS</scp> â€Care Atrial Fibrillation Registry. <i>Clinical Cardiology</i> , 2014, 37, 7-13.	0.7	105
542	Combined Use of Warfarin and Oral <scp>P2Y12</scp> Inhibitors in Patients With Atrial Fibrillation and Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2014, 37, 152-159.	0.7	3
543	The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the <scp>ASCENDâ€HF T</scp>rial. <i>European Journal of Heart Failure</i> , 2014, 16, 334-341.	2.9	56
544	Chest pain in patients with heart failure: why history may matter. <i>European Heart Journal</i> , 2014, 35, 3408-3409.	1.0	4
545	Peripheral Arterial Testing Before Lower Extremity Amputation Among Medicare Beneficiaries, 2000 to 2010. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 142-150.	0.9	41
546	Shortâ€and Longâ€term Rehospitalization and Mortality for Heart Failure in 4 Racial/Ethnic Populations. <i>Journal of the American Heart Association</i> , 2014, 3, e001134.	1.6	67
547	Representativeness of RELAX-AHF Clinical Trial Population in Acute Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 259-268.	0.9	37
548	Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome. <i>Stroke</i> , 2014, 45, 2745-2749.	1.0	37
549	Impact of an Expanded Hospital Recognition Program for Heart Failure Quality of Care. <i>Journal of the American Heart Association</i> , 2014, 3, e000950.	1.6	11
550	Patterns of Care Quality and Prognosis Among Hospitalized Ischemic Stroke Patients With Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2014, 3, e000905.	1.6	31
551	Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1632.	3.8	469
552	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2209.	3.8	35
553	Racial/Ethnic Differences in Process of Care and Outcomes Among Patients Hospitalized With Intracerebral Hemorrhage. <i>Stroke</i> , 2014, 45, 3243-3250.	1.0	35
554	GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 673-679.	1.6	41
555	Clinical Commentary on â€œCertain Uncertainty: Life After Stroke From the Patientâ€™s Perspectiveâ€: <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 970-970.	0.9	14
556	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	0.7	57
557	PERMANENT PACEMAKER USE AND OUTCOMES IN OLDER PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION. <i>Journal of the American College of Cardiology</i> , 2014, 63, A860.	1.2	1
558	Thrombolytic Therapy for Thrombosis of Continuous Flow Ventricular Assist Devices. <i>Journal of Cardiac Failure</i> , 2014, 20, 91-97.	0.7	55

#	ARTICLE	IF	CITATIONS
559	Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. <i>American Heart Journal</i> , 2014, 167, 846-852.e2.	1.2	218
560	Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2014, 20, 23-30.	0.7	20
561	The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. <i>American Heart Journal</i> , 2014, 167, 335-341.	1.2	81
562	Prescribing warfarin at discharge for heart failure patients: Findings from the Get With The Guidelines-Heart Failure Registry. <i>International Journal of Cardiology</i> , 2014, 172, e322-e323.	0.8	2
563	Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. <i>European Heart Journal</i> , 2014, 35, 250-256.	1.0	148
564	Authors' Reply. <i>Clinical Cardiology</i> , 2014, 37, 323-323.	0.7	0
565	Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 840-846.	0.8	14
566	Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. <i>American Heart Journal</i> , 2014, 168, 721-730.e3.	1.2	289
567	Guideline-Directed Low-Density Lipoprotein Management in High-Risk Patients With Ischemic Stroke. <i>Stroke</i> , 2014, 45, 3343-3351.	1.0	28
568	Strategies Used by Hospitals to Improve Speed of Tissue-Type Plasminogen Activator Treatment in Acute Ischemic Stroke. <i>Stroke</i> , 2014, 45, 1387-1395.	1.0	81
569	Associations Between Anticoagulation Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 670-679.	0.9	5
570	Hospitalized Hemorrhagic Stroke Patients with Renal Insufficiency: Clinical Characteristics, Care Patterns, and Outcomes. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 2265-2273.	0.7	26
571	Transient and Persistent Worsening Renal Function during Acute Heart Failure Hospitalization: Insights from the ADHERE Registry Linked to Medicare Claims. <i>Journal of Cardiac Failure</i> , 2014, 20, S14.	0.7	0
572	Differential Response to Low Dose Dopamine or Nesiritide in Patients with Acute Heart Failure and Renal Dysfunction in Accordance to LV EF: Sub-Group Analysis of the ROSE AHF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, S94.	0.7	0
573	A Stepwise Pharmacological Care Algorithm for Cardiorenal Syndrome for Acute Heart Failure: Insights from DOSE-AHF, CARRESS-HF, and ROSE-AHF. <i>Journal of Cardiac Failure</i> , 2014, 20, S13.	0.7	1
574	Clinical Characteristics and Outcomes of Patients with Discordant Findings at Right Heart Catheterization and Cardiopulmonary Exercise Testing. <i>Journal of Cardiac Failure</i> , 2014, 20, S49-S50.	0.7	0
575	Cardiovascular Phenotype in HFpEF Patients With or Without Diabetes. <i>Journal of the American College of Cardiology</i> , 2014, 64, 541-549.	1.2	157
576	Chronic Kidney Disease and Bleeding Complications After Intravenous Thrombolytic Therapy for Acute Ischemic Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 929-935.	0.9	35

#	ARTICLE	IF	CITATIONS
577	Resting Ventricular Vascular Function and Exercise Capacity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 580-589.	1.6	40
578	Characteristics and Outcomes of Patients With Heart Failure and Discordant Findings by Right-Sided Heart Catheterization and Cardiopulmonary Exercise Testing. <i>American Journal of Cardiology</i> , 2014, 114, 1059-1064.	0.7	17
579	Effect of Serelaxin on Mode of Death in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1591-1598.	1.2	56
580	Hospital Variation in Intravenous Inotrope Use for Patients Hospitalized With Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 251-260.	1.6	28
581	Insurance Status and Outcome after Intracerebral Hemorrhage: Findings from Get With The Guidelines-Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 283-292.	0.7	31
582	Trends in the Use and Outcomes of Ventricular Assist Devices Among Medicare Beneficiaries, 2006 Through 2011. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1395-1404.	1.2	56
583	Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction. <i>American Heart Journal</i> , 2014, 167, 480-488.e1.	1.2	18
584	Outcomes of Medicare Beneficiaries With Heart Failure and Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2014, 2, 41-48.	1.9	52
585	Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. <i>American Heart Journal</i> , 2014, 167, 369-375.e2.	1.2	57
586	Use of Renin-Angiotensin System Blockers in Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 227-235.	0.9	10
587	Current quality of cardiovascular prevention for Million Hearts: An analysis of 147,038 outpatients from The Guideline Advantage. <i>American Heart Journal</i> , 2014, 168, 398-404.	1.2	26
588	Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter-Defibrillator Versus Defibrillator Therapy Alone. <i>Annals of Internal Medicine</i> , 2014, 160, 603.	2.0	27
589	In heart failure, automatic implant-based telemonitoring reduced a composite of cardiac events and mortality. <i>Annals of Internal Medicine</i> , 2014, 161, JC10.	2.0	0
590	Abstract MP28: Heart Rate At Hospital Discharge Is Associated With Adverse Long Term Outcomes In Patients With Heart Failure. <i>Circulation</i> , 2014, 129, .	1.6	0
591	Abstract 15556: Effects of Left Ventricular Assist Device Support on microRNA Levels. <i>Circulation</i> , 2014, 130, .	1.6	0
592	QRS Duration, Bundle-Branch Block Morphology, and Outcomes Among Older Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 617.	3.8	86
593	Ultrafiltration in Heart Failure with Cardiorenal Syndrome. <i>New England Journal of Medicine</i> , 2013, 368, 1157-1160.	13.9	11
594	Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment. <i>American Heart Journal</i> , 2013, 165, 862-868.	1.2	11

#	ARTICLE	IF	CITATIONS
595	Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. <i>American Heart Journal</i> , 2013, 165, 979-986.e1.	1.2	74
596	Clinical Effectiveness of Anticoagulation Therapy Among Older Patients With Heart Failure and Without Atrial Fibrillation: Findings From the ADHERE Registry Linked to Medicare Claims. <i>Journal of Cardiac Failure</i> , 2013, 19, 401-407.	0.7	7
597	Does Atrial Fibrillation Affect Outcomes in Patients Admitted With Acute Heart Failure? Insights From the Ascend-Hf Trial. <i>Canadian Journal of Cardiology</i> , 2013, 29, S147-S148.	0.8	0
598	Cardiohepatic Interactions in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2397-2405.	1.2	240
599	Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2013, 6, 862-868.	1.6	21
600	Targeting the Kidney in Acute Heart Failure: Can Old Drugs Provide New Benefit?. <i>Circulation: Heart Failure</i> , 2013, 6, 1087-1094.	1.6	27
601	Targeting anti- $\beta_1$ -adrenergic receptor antibodies for dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2013, 15, 724-729.	2.9	47
602	Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1177-1183.	1.2	78
603	Preventing Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 44.	3.8	3
604	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	2.9	39
605	Comparative Effectiveness of Pharmacotherapies for Prevention of Atrial Fibrillation Following Coronary Artery Bypass Surgery. <i>American Journal of Cardiology</i> , 2013, 112, 954-960.	0.7	17
606	Exercise Training and Implantable Cardioverter-Defibrillator Shocks in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 142-148.	1.9	56
607	Generalizability of RELAX-AHF Clinical Trial Patients to a Large US Registry. <i>Journal of Cardiac Failure</i> , 2013, 19, S27.	0.7	0
608	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: Findings from the Get With The Guideline <sup>®</sup> Heart Failure Registry. <i>American Heart Journal</i> , 2013, 166, 1063-1071.e3.	1.2	55
609	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013, 1, 523-530.	1.9	22
610	Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. <i>American Heart Journal</i> , 2013, 165, 987-994.e1.	1.2	46
611	Associations Between Use of the Hospitalist Model and Quality of Care and Outcomes of Older Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 445-453.	1.9	30
612	Dysphagia Screening and Hospital-acquired Pneumonia in Patients with Acute Ischemic Stroke: Findings from Get with the Guidelines <sup>®</sup> Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2013, 22, e301-e309.	0.7	44



#	ARTICLE	IF	CITATIONS
613	Medical Resource Use, Costs, and Quality of Life in Patients With Acute Decompensated Heart Failure: Findings From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2013, 19, 611-620.	0.7	12
614	Racial/Ethnic Differences in B-Type Natriuretic Peptide Levels and Their Association With Care and Outcomes Among Patients Hospitalized With Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 345-352.	1.9	32
615	Validated, Electronic Health Record Deployable Prediction Models for Assessing Patient Risk of 30-Day Rehospitalization and Mortality in Older Heart Failure Patients. <i>JACC: Heart Failure</i> , 2013, 1, 245-251.	1.9	95
616	Nesiritide Administration in Patients Hospitalized for Acute Decompensated Heart Failure: Does Timing Matter?. <i>Journal of Cardiac Failure</i> , 2013, 19, S66.	0.7	0
617	Temporal Trends and Predictors in the Use of Aldosterone Antagonists Post-Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 35-40.	1.2	46
618	Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: Findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). <i>American Heart Journal</i> , 2013, 166, 349-356.	1.2	49
619	Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. <i>American Heart Journal</i> , 2013, 165, 567-574.e6.	1.2	54
620	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1268.	3.8	976
621	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. <i>Journal of Cardiac Failure</i> , 2013, 19, 371-389.	0.7	53
622	In Reply: B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: Insights from the ADHERE registry. <i>American Heart Journal</i> , 2013, 165, e3.	1.2	4
623	Predictors of Adherence to Performance Measures in Patients with Acute Myocardial Infarction. <i>American Journal of Medicine</i> , 2013, 126, 74.e1-74.e9.	0.6	47
624	The meanings associated with medicines in heart failure patients. <i>European Journal of Cardiovascular Nursing</i> , 2013, 12, 276-283.	0.4	12
625	Dysphagia in the Setting of Left Ventricular Assist Device Hemolysis. <i>ASAIO Journal</i> , 2013, 59, 322-323.	0.9	5
626	Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome From Acute Ischemic Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2480.	3.8	662
627	A Crisis of the Heart. <i>ASAIO Journal</i> , 2013, 59, 668-670.	0.9	17
628	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2533.	3.8	410
629	Priorities for Comparative Effectiveness Reviews in Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 139-147.	0.9	7
630	Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 534-542.	0.9	25



#	ARTICLE	IF	CITATIONS
631	Predictors of Incident Heart Failure Hospitalizations Among Patients With Impaired Glucose Tolerance. <i>Circulation: Heart Failure</i> , 2013, 6, 203-210.	1.6	26
632	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. <i>Circulation: Heart Failure</i> , 2013, 6, 727-732.	1.6	103
633	Ten-Year Experience With Extended Criteria Cardiac Transplantation. <i>Circulation: Heart Failure</i> , 2013, 6, 1230-1238.	1.6	39
634	Comparison of Performance Achievement Award Recognition With Primary Stroke Center Certification for Acute Ischemic Stroke Care. <i>Journal of the American Heart Association</i> , 2013, 2, e000451.	1.6	18
635	Who Enrolls in the Medicare Part D Prescription Drug Benefit Program? Medication Use Among Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2013, 2, e000242.	1.6	8
636	Racial and Ethnic Differences in Outcomes in Older Patients With Acute Ischemic Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 284-292.	0.9	67
637	Use of Hydralazineâ€¦Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction. <i>Journal of the American Heart Association</i> , 2013, 2, e000214.	1.6	33
638	Achievement of Guideline-Concordant Care and In-Hospital Outcomes in Patients With Coronary Artery Disease in Teaching and Nonteaching Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 58-65.	0.9	25
639	Age Differences in the Use of Implantable Cardioverterâ€¦Defibrillators Among Older Patients Hospitalized with Heart Failure. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 664-671.	0.8	11
640	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	2.9	182
641	Relationship of Race/Ethnicity With Doorâ€¦toâ€¦Balloon Time and Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for <sc>ST</sc>â€¦Elevation Myocardial Infarction: Findings From Get With the Guidelinesâ€œCoronary Artery Disease. <i>Clinical Cardiology</i> , 2013, 36, 749-756.	0.7	44
642	Postdischarge International Normalized Ratio Testing and Longâ€¦term Clinical Outcomes of Patients With Heart Failure Receiving Warfarin: Findings From the <sc>ADHERE</sc> Registry Linked to Medicare Claims. <i>Clinical Cardiology</i> , 2013, 36, 757-765.	0.7	3
643	Racial Differences in the Prevalence and Outcomes of Atrial Fibrillation Among Patients Hospitalized With Heart Failure. <i>Journal of the American Heart Association</i> , 2013, 2, e000200.	1.6	43
644	Markers of Decongestion, Dyspnea Relief, and Clinical Outcomes Among Patients Hospitalized With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 240-245.	1.6	147
645	A Risk Score for Inâ€¦Hospital Death in Patients Admitted With Ischemic or Hemorrhagic Stroke. <i>Journal of the American Heart Association</i> , 2013, 2, e005207.	1.6	73
646	Patterns of Emergency Medical Services Use and Its Association With Timely Stroke Treatment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 262-269.	0.9	144
647	Synthesizing Lessons Learned From Get With The Guidelines. <i>Circulation</i> , 2013, 128, 2447-2460.	1.6	106
648	IVC Filters and Postoperative Outcomes in Patients Undergoing Bariatric Surgery: A Meta-analysis. <i>Chest</i> , 2013, 144, 849A.	0.4	0

#	ARTICLE	IF	CITATIONS
649	Anticoagulation and Clinical Outcomes in Heart Failure Patients With Atrial Fibrillation: Findings From the ADHERE Registry. <i>Journal of Atrial Fibrillation</i> , 2013, 6, 953.	0.5	0
650	Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 735-741.	1.6	27
651	Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 594-600.	0.9	53
652	Trends in Use of Implantable Cardioverter-Defibrillator Therapy Among Patients Hospitalized for Heart Failure. <i>Circulation</i> , 2012, 125, 1094-1101.	1.6	124
653	Relationship of National Institutes of Health Stroke Scale to 30-Day Mortality in Medicare Beneficiaries With Acute Ischemic Stroke. <i>Journal of the American Heart Association</i> , 2012, 1, 42-50.	1.6	116
654	Care and Outcomes of Asian-American Acute Myocardial Infarction Patients: Findings From the American Heart Association Get With The Guidelines-Coronary Artery Disease Program. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 126-133.	0.9	28
655	Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Trial. <i>Circulation: Heart Failure</i> , 2012, 5, 653-659.	1.6	107
656	Addressing the 100% of Heart Failure: A Call for Complete Care of All Ages. <i>Circulation: Heart Failure</i> , 2012, 5, 667-668.	1.6	0
657	Presence of Atrial Fibrillation Is Independently Associated With Adverse Outcomes in Patients Hospitalized With Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 191-201.	1.6	106
658	Prediction Is Very Hard, Especially About the Future. <i>Archives of Internal Medicine</i> , 2012, 172, 117.	4.3	7
659	Incidence and Prevalence of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993-2007. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 85-93.	0.9	476
660	Outcomes of Medicare Beneficiaries Undergoing Catheter Ablation for Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 2200-2207.	1.6	138
661	Guideline Adherence After ST-Segment Elevation Versus Non-ST Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 654-661.	0.9	42
662	Response to Letter Regarding Article, "Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices." <i>Circulation: Heart Failure</i> , 2012, 5, .	1.6	0
663	Get With The Guidelines Program Participation, Process of Care, and Outcome for Medicare Patients Hospitalized With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 37-43.	0.9	115
664	Patterns, Predictors, Variations, and Temporal Trends in Emergency Medical Service Hospital Prenotification for Acute Ischemic Stroke. <i>Journal of the American Heart Association</i> , 2012, 1, e002345.	1.6	36
665	National Survey of Hospital Strategies to Reduce Heart Failure Readmissions. <i>Circulation: Heart Failure</i> , 2012, 5, 680-687.	1.6	97
666	Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System. <i>Archives of Internal Medicine</i> , 2012, 172, 1582.	4.3	178

#	ARTICLE	IF	CITATIONS
667	Comparison of 30-Day Mortality Models for Profiling Hospital Performance in Acute Ischemic Stroke With vs Without Adjustment for Stroke Severity. JAMA - Journal of the American Medical Association, 2012, 308, 257-64.	3.8	153
668	Trends in Clinical, Demographic, and Biochemical Characteristics of Patients With Acute Myocardial Infarction From 2003 to 2008: A Report From the American Heart Association Get With The Guidelines Coronary Artery Disease Program. Journal of the American Heart Association, 2012, 1, e001206.	1.6	31
669	Care and Outcomes of Hispanic Patients Admitted With Heart Failure With Preserved or Reduced Ejection Fraction. Circulation: Heart Failure, 2012, 5, 167-175.	1.6	48
670	Emergency Medical Service Hospital Prenotification Is Associated With Improved Evaluation and Treatment of Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 514-522.	0.9	192
671	Representativeness of the Get With The Guidelinesâ€“Stroke Registry. Stroke, 2012, 43, 44-49.	1.0	108
672	Times From Symptom Onset to Hospital Arrival in the Get With The Guidelinesâ€“Stroke Program 2002 to 2009. Stroke, 2012, 43, 1912-1917.	1.0	136
673	Associations Between Aldosterone Antagonist Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2012, 308, 2097.	3.8	125
674	Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. New England Journal of Medicine, 2012, 367, 2296-2304.	13.9	790
675	Outcomes Associated With Warfarin Use in Older Patients With Heart Failure and Atrial Fibrillation and a Cardiovascular Implantable Electronic Device: Findings From the ADHERE Registry Linked to Medicare Claims. Clinical Cardiology, 2012, 35, 649-657.	0.7	11
676	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, e29-e84.	0.4	107
677	Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm, 2012, 9, 1403-1408.	0.3	26
678	1114 ROBOTIC PARTIAL NEPHRECTOMY VERSUS LAPAROSCOPIC CRYOABLATION FOR THE SMALL RENAL MASS. Journal of Urology, 2012, 187, .	0.2	0
679	Troponin I in acute decompensated heart failure: insights from the ASCENDâ€“HF study. European Journal of Heart Failure, 2012, 14, 1257-1264.	2.9	101
680	Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen Activator. Stroke, 2012, 43, 2293-2299.	1.0	196
681	Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction. Circulation, 2012, 126, 65-75.	1.6	681
682	Patient and hospital characteristics associated with traditional measures of inpatient quality of care for patients with heart failure. American Heart Journal, 2012, 163, 239-245.e3.	1.2	25
683	Data quality in the American Heart Association Get With The Guidelines-Stroke (CWTC-Stroke): Results from a National Data Validation Audit. American Heart Journal, 2012, 163, 392-398.e1.	1.2	145
684	Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. American Heart Journal, 2012, 163, 430-437.e3.	1.2	89

#	ARTICLE	IF	CITATIONS
685	International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. <i>American Heart Journal</i> , 2012, 163, 804-811.	1.2	32
686	Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure. <i>American Heart Journal</i> , 2012, 163, 946-953.e1.	1.2	3
687	B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: Insights from the Acute Decompensated Heart Failure National Registry. <i>American Heart Journal</i> , 2012, 163, 994-1001.	1.2	12
688	130 Extended Criteria Cardiac Transplantation Versus Destination Therapy Left Ventricular Assist Device Therapy in the Continuous Flow Era. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, S52-S53.	0.3	0
689	Patient Characteristics From a Regional Multicenter Database of Acute Decompensated Heart Failure in Asia Pacific (ADHERE Internationalâ€™Asia Pacific). <i>Journal of Cardiac Failure</i> , 2012, 18, 82-88.	0.7	155
690	Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 94-106.	0.7	93
691	Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 265-281.	0.7	50
692	Utilization of Hospice and Predicted Mortality Risk Among Older Patients Hospitalized With Heart Failure: Findings From GWTG-HF. <i>Journal of Cardiac Failure</i> , 2012, 18, 471-477.	0.7	21
693	Early International Normalized Ratio (INR) Monitoring and Long-Term Clinical Outcomes in Warfarin Users with Heart Failure: Findings from ADHERE Linked with Medicare Claims. <i>Journal of Cardiac Failure</i> , 2012, 18, S92.	0.7	0
694	Admission Heart Rate and In-Hospital Outcomes in Patients Hospitalized for Heart Failure in Sinus Rhythm and Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2012, 18, S73-S74.	0.7	0
695	Do BNP Levels and Prognostic Value Vary by Race/Ethnicity in Patients Hospitalized With Heart Failure?. <i>Journal of Cardiac Failure</i> , 2012, 18, S80-S81.	0.7	0
696	819 Does a Low Ejection Fraction Predict Mortality? Insights From the ASCEND-HF Trial. <i>Canadian Journal of Cardiology</i> , 2012, 28, S413-S414.	0.8	0
697	Completion of Guidelineâ€™Recommended Initial Evaluation of Atrial Fibrillation. <i>Clinical Cardiology</i> , 2012, 35, 585-593.	0.7	7
698	Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. <i>American Heart Journal</i> , 2012, 164, 763-770.e3.	1.2	95
699	Assessment of Dyspnea in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1441-1448.	1.2	35
700	Are Racial/Ethnic Gaps in the Use of Cardiac Resynchronization Therapy Narrowing?. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1577-1578.	1.2	21
701	Age and Gender Differences in Quality of Care and Outcomes for Patients with ST-segment Elevation Myocardial Infarction. <i>American Journal of Medicine</i> , 2012, 125, 1000-1009.	0.6	128
702	DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2012, 59, E1029.	1.2	3

#	ARTICLE	IF	CITATIONS
703	ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2427-2463.	1.2	352
704	Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2600-8.	3.8	142
705	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 1023-1082.	0.7	46
706	Quality of Care and Outcomes Among Patients With Acute Myocardial Infarction by Level of Kidney Function at Admission: Report From the Get With The Guidelines Coronary Artery Disease Program. <i>Clinical Cardiology</i> , 2012, 35, 541-547.	0.7	18
707	Trends in Smoking Cessation Counseling: Experience From American Heart Association's Get With The Guidelines. <i>Clinical Cardiology</i> , 2012, 35, 396-403.	0.7	7
708	Reperfusion Strategies and Quality of Care in 5339 Patients Age 80 Years or Older Presenting With ST-Elevation Myocardial Infarction: Analysis from Get With The Guidelines's Coronary Artery Disease. <i>Clinical Cardiology</i> , 2012, 35, 632-640.	0.7	28
709	Predicting Costs Among Medicare Beneficiaries With Heart Failure. <i>American Journal of Cardiology</i> , 2012, 109, 705-711.	0.7	27
710	Successful Organ Donation After Long-Term Circulatory Support With Nonpulsatile Mechanical Support. <i>American Journal of Transplantation</i> , 2012, 12, 1962-1963.	2.6	2
711	2035 FAMILY HISTORY OF PROSTATE CANCER DOES NOT INCREASE THE RISK OF DETECTION OF PROSTATE CANCER NOR HIGH GRADE DISEASE IN MEN UNDERGOING INITIAL PROSTATE BIOPSY. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
712	Systematic Review of the Incidence of Sudden Cardiac Death in the United States. <i>Journal of the American College of Cardiology</i> , 2011, 57, 794-801.	1.2	287
713	The Importance of Consistent, High-Quality Acute Myocardial Infarction and Heart Failure Care. <i>Journal of the American College of Cardiology</i> , 2011, 58, 637-644.	1.2	29
714	Device Therapy in Heart Failure Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 889-896.	1.2	50
715	Payment Source, Quality of Care, and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1465-1471.	1.2	47
716	Changes in Myocardial Infarction Guideline Adherence as a Function of Patient Risk. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1760-1765.	1.2	42
717	Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 365, 32-43.	13.9	1,133
718	Nesiritide in Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 365, 1547-1547.	13.9	4
719	967 C-INDEX ASSOCIATES WITH FUNCTIONAL OUTCOMES AFTER LAPAROSCOPIC PARTIAL NEPHRECTOMY. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
720	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). <i>American Heart Journal</i> , 2011, 161, 418-424.e3.	1.2	35

#	ARTICLE	IF	CITATIONS
721	Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure. <i>American Heart Journal</i> , 2011, 161, 746-754.	1.2	83
722	Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. <i>American Heart Journal</i> , 2011, 161, 1024-1030.e3.	1.2	196
723	Do heart failure disease management programs make financial sense under a bundled payment system?. <i>American Heart Journal</i> , 2011, 161, 916-922.	1.2	17
724	Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: Findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). <i>American Heart Journal</i> , 2011, 162, 283-290.e2.	1.2	17
725	Quality of care for sudden cardiac arrest: Proposed steps to improve the translation of evidence into practice. <i>American Heart Journal</i> , 2011, 162, 222-231.	1.2	9
726	Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure. <i>American Heart Journal</i> , 2011, 162, 480-486.e3.	1.2	21
727	Improvement in use of anticoagulation therapy in patients with ischemic stroke: Results from Get With The Guidelines-Stroke. <i>American Heart Journal</i> , 2011, 162, 692-699.e2.	1.2	34
728	Regional differences in clinical profile, quality of care, and outcomes among Hispanic patients hospitalized with acute myocardial infarction in the Get with Guidelines-Coronary Artery Disease (GWTG-CAD) Registry. <i>American Heart Journal</i> , 2011, 162, 988-995.e4.	1.2	13
729	508 Acute heart failure: Canadian perspectives from an RCT and a registry. <i>Canadian Journal of Cardiology</i> , 2011, 27, S246.	0.8	0
730	Use and Predictors of Heart Failure Disease Management Referral in Patients Hospitalized With Heart Failure: Insights From the Get With the Guidelines Program. <i>Journal of Cardiac Failure</i> , 2011, 17, 431-439.	0.7	17
731	Predictors of Hospital Length of Stay in Heart Failure: Findings from Get With the Guidelines. <i>Journal of Cardiac Failure</i> , 2011, 17, 649-656.	0.7	73
732	Association between VE-VCO <sub>2</sub> Slope and Resting Hemodynamic Measurements in Ambulatory Heart Failure (HF) Patients: An Analysis from the Duke Advanced HF Database. <i>Journal of Cardiac Failure</i> , 2011, 17, S8-S9.	0.7	0
733	Cystatin C as a Biomarker of Worsening Renal Function in Acute Heart Failure: Insights from the DOSE Study. <i>Journal of Cardiac Failure</i> , 2011, 17, S58.	0.7	1
734	International Variation in Use of Anticoagulation among Heart Failure Patients with Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2011, 17, S72.	0.7	0
735	Clinical Outcomes at 180 days in the ASCEND-HF Trial: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 971.	0.7	7
736	Non-Evidence-Based ICD Implantations in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 43.	3.8	207
737	Review: Cardiac resynchronization reduces mortality and hospitalizations in patients with either more or less symptomatic HF. <i>Annals of Internal Medicine</i> , 2011, 155, JC2.	2.0	0
738	Postoperative Inotrope and Vasopressor Use Following CABG: Outcome Data from the CAPS-Care Study. <i>Journal of Cardiac Surgery</i> , 2011, 26, 572-578.	0.3	36



#	ARTICLE	IF	CITATIONS
739	Advanced Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 77.	1.6	2
740	Patterns and Predictors of Evidence-Based Medication Continuation Among Hospitalized Heart Failure Patients (from Get With the Guidelinesâ€“Heart Failure). <i>American Journal of Cardiology</i> , 2011, 107, 1818-1823.	0.7	67
741	Associations of Patient Demographic Characteristics and Regional Physician Density With Early Physician Follow-Up Among Medicare Beneficiaries Hospitalized With Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 985-991.	0.7	39
742	Pharmacologic Prophylaxis for Venous Thromboembolism and 30â€“Day Outcomes Among Older Patients Hospitalized With Heart Failure: An Analysis From the ADHERE National Registry Linked to Medicare Claims. <i>Clinical Cardiology</i> , 2011, 34, 682-688.	0.7	12
743	Diuretic Strategies in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 364, 797-805.	13.9	1,363
744	Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. <i>European Journal of Heart Failure</i> , 2011, 13, 945-952.	2.9	60
745	Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke. <i>Circulation</i> , 2011, 123, 750-758.	1.6	510
746	Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes. <i>Circulation: Heart Failure</i> , 2011, 4, 628-636.	1.6	199
747	Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices. <i>Circulation: Heart Failure</i> , 2011, 4, 779-784.	1.6	239
748	Quality of Care and Outcomes in Women Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 589-598.	1.6	46
749	Discharge to a Skilled Nursing Facility and Subsequent Clinical Outcomes Among Older Patients Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 293-300.	1.6	165
750	Incremental Value of Clinical Data Beyond Claims Data in Predicting 30-Day Outcomes After Heart Failure Hospitalization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 60-67.	0.9	96
751	Minding the Gap Between Efforts to Reduce Readmissions and Disparities. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 715.	3.8	29
752	Outcomes in Mild or Rapidly Improving Stroke Not Treated With Intravenous Recombinant Tissue-Type Plasminogen Activator. <i>Stroke</i> , 2011, 42, 3110-3115.	1.0	187
753	Improving Door-to-Needle Times in Acute Ischemic Stroke. <i>Stroke</i> , 2011, 42, 2983-2989.	1.0	313
754	Hospital-Level Variation in Mortality and Rehospitalization for Medicare Beneficiaries With Acute Ischemic Stroke. <i>Stroke</i> , 2011, 42, 159-166.	1.0	120
755	Resource Use in the Last 6 Months of Life Among Medicare Beneficiaries With Heart Failure, 2000-2007. <i>Archives of Internal Medicine</i> , 2011, 171, 196.	4.3	146
756	Comparison of Composite Measure Methodologies for Rewarding Quality of Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 610-618.	0.9	40

#	ARTICLE	IF	CITATIONS
757	The Need for Multiple Measures of Hospital Quality. <i>Circulation</i> , 2011, 124, 712-719.	1.6	62
758	Obstructive Sleep Apnea and Postoperative Outcome. <i>Chest</i> , 2011, 140, 342A.	0.4	0
759	Afternoon Adenoma Detection Rate in Half Day Blocks vs. All Day Procedures: Is There a Difference?. <i>American Journal of Gastroenterology</i> , 2011, 106, S563-S564.	0.2	0
760	Abstract P92: Racial Differences in End of Life Care in Medicare Beneficiaries With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, .	0.9	0
761	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. <i>Circulation: Heart Failure</i> , 2010, 3, 314-325.	1.6	134
762	Process of Care Performance Measures and Long-Term Outcomes in Patients Hospitalized With Heart Failure. <i>Medical Care</i> , 2010, 48, 210-216.	1.1	85
763	Rapid Change in Prescribing Behavior in Hospitals Participating in Get With The Guidelinesâ€“Stroke After Release of the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) Clinical Trial Results. <i>Stroke</i> , 2010, 41, 2094-2097.	1.0	12
764	Use of Guidelineâ€“Recommended Therapies for Heart Failure in the Medicare Population. <i>Clinical Cardiology</i> , 2010, 33, 400-405.	0.7	22
765	Quality of Care and In-Hospital Outcomes in Patients With Coronary Heart Disease in Rural and Urban Hospitals (from Get With the Guidelinesâ€“Coronary Artery Disease Program). <i>American Journal of Cardiology</i> , 2010, 105, 139-143.	0.7	33
766	Long-Term Outcomes of Medicare Beneficiaries With Worsening Renal Function During Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2010, 105, 1786-1793.	0.7	66
767	Left Ventricular Assist Device Destination Therapy Versus Extended Criteria Cardiac Transplant. <i>Annals of Thoracic Surgery</i> , 2010, 89, 1205-1210.	0.7	77
768	A Validated Risk Score for In-Hospital Mortality in Patients With Heart Failure From the American Heart Association Get With the Guidelines Program. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 25-32.	0.9	400
769	Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 291-302.	0.9	296
770	Regional Differences in Quality of Care and Outcomes for the Treatment of Acute Coronary Syndromes. <i>Critical Pathways in Cardiology</i> , 2010, 9, 1-7.	0.2	31
771	Racial and Ethnic Differences in the Treatment of Acute Myocardial Infarction. <i>Circulation</i> , 2010, 121, 2294-2301.	1.6	137
772	Early Physician Follow-up and 30-Day Readmission Among Older Patients With Heart Failureâ€“Reply. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 743.	3.8	0
773	Relationship Between Early Physician Follow-up and 30-Day Readmission Among Medicare Beneficiaries Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1716.	3.8	852
774	Aldosterone Antagonists in Patients With Heart Failureâ€“Reply. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 833.	3.8	0

#	ARTICLE	IF	CITATIONS
775	Treatment and Risk in Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 309-315.	0.9	72
776	Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 7-13.	1.6	72
777	Recent Nationwide Trends in Discharge Statin Treatment of Hospitalized Patients With Stroke. <i>Stroke</i> , 2010, 41, 1508-1513.	1.0	39
778	Patterns and Predictors of Discharge Statin Prescription Among Hospitalized Patients With Intracerebral Hemorrhage. <i>Stroke</i> , 2010, 41, 2271-2277.	1.0	3
779	A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. <i>Kidney International</i> , 2010, 77, 239-246.	2.6	62
780	Efficacy and safety of nesiritide in patients with acute decompensated heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 159-169.	0.6	3
781	141 STAGE MIGRATION IN PROSTATE CANCER AT RADICAL PROSTATECTOMY DURING THE PSA ERA IS ASSOCIATED WITH RELATIVELY CONSTANT GLEASON SCORE. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
782	Combination of Loop Diuretics With Thiazide-Type Diuretics in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1527-1534.	1.2	323
783	Risk Score for In-Hospital Ischemic Stroke Mortality Derived and Validated Within the Get With The Guidelinesâ€“Stroke Program. <i>Circulation</i> , 2010, 122, 1496-1504.	1.6	232
784	Admission, Discharge, or Change in BNP and Long-Term Mortality: Data from OPTIMIZE-HF Linked with Medicare Claims. <i>Journal of Cardiac Failure</i> , 2010, 16, S7-S8.	0.7	0
785	Use and Predictors of Heart Failure Disease Management Referral in Patients Hospitalized With Heart Failure: Insights from the American Heart Association â€“ Get with the Guidelines Program. <i>Journal of Cardiac Failure</i> , 2010, 16, S78.	0.7	0
786	Characterization of Heart Failure Patients With Preserved Systolic Function: A Comparison between ADHERE-US Registry and ADHERE-International Registry. <i>Journal of Cardiac Failure</i> , 2010, 16, S79.	0.7	0
787	Venous Thromboembolism Prophylaxis among Elderly Heart Failure Patients and 60-Day Outcomes: An Analysis from ADHERE Linked to Medicare Claims. <i>Journal of Cardiac Failure</i> , 2010, 16, S92.	0.7	0
788	Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time?. <i>American Heart Journal</i> , 2010, 159, 207-214.	1.2	37
789	Relationships between emerging measures of heart failure processes of care and clinical outcomes. <i>American Heart Journal</i> , 2010, 159, 406-413.	1.2	56
790	Association of insurance status with inpatient treatment for coronary artery disease: Findings from the Get With the Guidelines program. <i>American Heart Journal</i> , 2010, 159, 1026-1036.	1.2	16
791	Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure. <i>American Heart Journal</i> , 2010, 160, 132-138.e1.	1.2	39
792	A review of dyspnea in acute heart failure syndromes. <i>American Heart Journal</i> , 2010, 160, 209-214.	1.2	58

#	ARTICLE	IF	CITATIONS
793	Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. <i>American Heart Journal</i> , 2010, 160, 885-892.	1.2	114
794	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). <i>American Heart Journal</i> , 2010, 160, 1130-1136.e3.	1.2	33
795	Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. <i>American Heart Journal</i> , 2010, 160, 605-618.e1.	1.2	21
796	Surgical Management of Bilateral Synchronous Kidney Tumors: Functional and Oncological Outcomes. <i>Journal of Urology</i> , 2010, 184, 865-872.	0.2	31
797	2008 IDENTIFICATION OF VARIABLES ASSOCIATED WITH INCREASED PAIN DURING TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
798	Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 633-641.	0.9	73
799	Outcomes of Medicare Beneficiaries With Ventricular Assist Devices—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1656.	3.8	0
800	BNP-Guided Heart Failure Therapy in Older Patients. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 2091.	3.8	1
801	Off-Hour Admission and In-Hospital Stroke Case Fatality in the Get With The Guidelines-Stroke Program. <i>Stroke</i> , 2009, 40, 569-576.	1.0	124
802	Influence of stroke subtype on quality of care in the Get With The Guidelines—Stroke Program. <i>Neurology</i> , 2009, 73, 709-716.	1.5	28
803	Quality of Care for Acute Coronary Syndrome Patients With Known Atherosclerotic Disease. <i>Circulation</i> , 2009, 120, 560-567.	1.6	68
804	Representativeness of a National Heart Failure Quality-of-Care Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 377-384.	0.9	82
805	Current Use of Beta Blockers in Patients With Reactive Airway Disease Who Are Hospitalized With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2009, 103, 295-300.	0.7	62
806	Door-to-Balloon Times in Hospitals Within the Get-With-The-Guidelines Registry After Initiation of the Door-to-Balloon (D2B) Alliance. <i>American Journal of Cardiology</i> , 2009, 103, 1051-1055.	0.7	63
807	Association Between Mortality and Persistent Use of Beta Blockers and Angiotensin-Converting Enzyme Inhibitors in Patients With Left Ventricular Systolic Dysfunction and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2009, 103, 1518-1524.	0.7	7
808	A change of heart. <i>Journal of Hospital Medicine</i> , 2009, 4, 131-136.	0.7	0
809	Role of guanylate cyclase modulators in decompensated heart failure. <i>Heart Failure Reviews</i> , 2009, 14, 309-319.	1.7	36
810	Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 271-277.	1.2	141

#	ARTICLE	IF	CITATIONS
811	Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines. American Heart Journal, 2009, 157, 111-117.e2.	1.2	270
812	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). American Heart Journal, 2009, 157, 219-228.	1.2	36
813	Influence of age on the management of heart failure: Findings from Get With the Guidelines“Heart Failure (GWTHG-HF). American Heart Journal, 2009, 157, 1010-1017.	1.2	58
814	Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. American Heart Journal, 2009, 157, 995-1000.	1.2	344
815	Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. American Heart Journal, 2009, 157, 957-970.	1.2	48
816	Variation in perioperative vasoactive therapy in cardiovascular surgical care: Data from the Society of Thoracic Surgeons. American Heart Journal, 2009, 158, 47-52.	1.2	39
817	Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials. American Heart Journal, 2009, 158, 422-430.	1.2	303
818	Weekend hospital admission and discharge for heart failure: Association with quality of care and clinical outcomes. American Heart Journal, 2009, 158, 451-458.	1.2	73
819	Characteristics and in-hospital outcomes for nonadherent patients with heart failure: Findings from Get With The Guidelines-Heart Failure (GWTHG-HF). American Heart Journal, 2009, 158, 644-652.	1.2	96
820	Impact of Left Ventricular Assist Device Bridging on Posttransplant Outcomes. Annals of Thoracic Surgery, 2009, 88, 1457-1461.	0.7	37
821	Clinical Effectiveness of Beta-Blockers in Heart Failure. Journal of the American College of Cardiology, 2009, 53, 184-192.	1.2	295
822	Hospital Variation and Characteristics of Implantable Cardioverter-Defibrillator Use in Patients With Heart Failure. Journal of the American College of Cardiology, 2009, 53, 416-422.	1.2	120
823	End Points for Clinical Trials in Acute Heart Failure Syndromes. Journal of the American College of Cardiology, 2009, 53, 2248-2258.	1.2	92
824	Predictors of Cardiac Rehabilitation Referral in Coronary Artery Disease Patients. Journal of the American College of Cardiology, 2009, 54, 515-521.	1.2	236
825	Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure. Journal of the American College of Cardiology, 2009, 54, 1280-1289.	1.2	129
826	Advancing care for acute heart failure“no time to relax. Lancet, The, 2009, 373, 1401-1402.	6.3	3
827	The Dissociation Between Door-to-Balloon Time Improvement and Improvements in Other Acute Myocardial Infarction Care Processes and Patient Outcomes. Archives of Internal Medicine, 2009, 169, 1411.	4.3	47
828	Use of Aldosterone Antagonists in Heart Failure. JAMA - Journal of the American Medical Association, 2009, 302, 1658.	3.8	231

#	ARTICLE	IF	CITATIONS
829	Weekend/Holiday Versus Weekday Hospital Discharge and Guideline Adherence (from the American Tj ETQq1 1 0.784314 rgBT /Overlo Cardiology, 2008, 102, 663-667.	0.7	17
830	Influence of Hospital Length of Stay for Heart Failure on Quality of Care. American Journal of Cardiology, 2008, 102, 1693-1697.	0.7	20
831	Infectious Complications in Extended Criteria Heart Transplantation. Journal of Heart and Lung Transplantation, 2008, 27, 1217-1221.	0.3	20
832	Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: Insights from American Heart Association's Get With the Guidelines program. American Heart Journal, 2008, 155, 1059-1067.	1.2	77
833	Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelinesâ€”Heart Failure Program study. American Heart Journal, 2008, 156, 674-681.	1.2	71
834	Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. American Heart Journal, 2008, 156, 1170-1176.	1.2	61
835	Features and Hospital Outcomes for Nonadherent Patients with Heart Failure: Findings from CWTC-HF. Journal of Cardiac Failure, 2008, 14, S7.	0.7	0
836	Weekend Hospital Admission for Heart Failure: Influence on Quality of Care, Length of Stay, and In-Hospital Mortality. Journal of Cardiac Failure, 2008, 14, S7-S8.	0.7	0
837	Translating Evidence into Practice: Use of Statins in Real-World Patients with Heart Failure. Heart Failure Clinics, 2008, 4, 217-223.	1.0	0
838	Sex Differences in Medical Care and Early Death After Acute Myocardial Infarction. Circulation, 2008, 118, 2803-2810.	1.6	455
839	Sex Differences in Hospital Risk-Adjusted Mortality Rates for Medicare Beneficiaries Undergoing CABG Surgeryâ€”Invited Commentary. Archives of Internal Medicine, 2008, 168, 2323.	4.3	0
840	Patient and Implanting Physician Factors Associated With Mortality and Complications After Implantable Cardioverter-Defibrillator Implantation, 2002â€”2005. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 240-249.	2.1	99
841	Incidence and Prevalence of Heart Failure in Elderly Persons, 1994-2003. Archives of Internal Medicine, 2008, 168, 418.	4.3	290
842	Implantable Cardioverter-Defibrillators, Heart Failure, and Patient Characteristicsâ€”Reply. JAMA - Journal of the American Medical Association, 2008, 299, .	3.8	0
843	Comparative Effectiveness of Î²-Blockers in Elderly Patients With Heart Failure. Archives of Internal Medicine, 2008, 168, 2422.	4.3	36
844	Early and Long-term Outcomes of Heart Failure in Elderly Persons, 2001-2005. Archives of Internal Medicine, 2008, 168, 2481.	4.3	154
845	Use of Cardiac Resynchronization Therapy in Patients Hospitalized With Heart Failure. Circulation, 2008, 118, 926-933.	1.6	89
846	Comparative effectiveness of angiotensin-converting-enzyme inhibitors: Is an ACE always an ace?. Cmaj, 2008, 178, 1316-1319.	0.9	13



#	ARTICLE	IF	CITATIONS
847	Long-term Outcomes and Costs of Ventricular Assist Devices Among Medicare Beneficiaries. JAMA - Journal of the American Medical Association, 2008, 300, 2398.	3.8	75
848	Association of Patient Case-Mix Adjustment, Hospital Process Performance Rankings, and Eligibility for Financial Incentives. JAMA - Journal of the American Medical Association, 2008, 300, 1897.	3.8	68
849	Impact of Heart Failure on Patients Undergoing Major Noncardiac Surgery. Anesthesiology, 2008, 108, 559-567.	1.3	265
850	A Decade of Short-Term Outcomes in Post-Cardiac Surgery Ventricular Assist Device Implantation. Circulation, 2007, 116, 606-612.	1.6	94
851	Sex Differences in the Use of Implantable Cardioverter-Defibrillators for Primary and Secondary Prevention of Sudden Cardiac Death. JAMA - Journal of the American Medical Association, 2007, 298, 1517-24.	3.8	247
852	Sex and Racial Differences in the Use of Implantable Cardioverter-Defibrillators Among Patients Hospitalized With Heart Failure. JAMA - Journal of the American Medical Association, 2007, 298, 1525-32.	3.8	365
853	Heart Failure With Preserved Left Ventricular Systolic Function Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. American Journal of Cardiology, 2007, 99, 1351-1356.	0.7	13
854	Medical Therapies and Invasive Treatments for Coronary Artery Disease by Body Mass: The Obesity Paradox in the Get With The Guidelines Database. American Journal of Cardiology, 2007, 100, 1331-1335.	0.7	130
855	Patterns and Implications of Abnormal Natriuretic Peptide Measurement in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes—Conflicts of interest: L. Kristin Newby receives research grants from Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, the Schering Plough Research Institute, and BMS/Sanofi and is a member of the speakers bureau and receives honoraria from BMS/Sanofi/Aventis. W. Frank Peacock receives research grants from and is a member of the speakers bureau and the consultant. American Journal of Cardiology, 2007, 100, 1727-1733.	0.7	5
856	Topical Anesthesia With EMLA Reduces Pain During Endomyocardial Biopsy: a Randomized Trial. Journal of Heart and Lung Transplantation, 2006, 25, 1164-1166.	0.3	2
857	Reliability of Heart Failure Patient Care: Initial Results from the American Heart Association's Get With The Guidelines (GWTG) Heart Failure Program. Journal of Cardiac Failure, 2006, 12, S95-S95.	0.7	0
858	Influence of the American Heart Association's Get With The Guidelines (GWTG) Program on the Quality of Care for Patients Hospitalized with Heart Failure. Journal of Cardiac Failure, 2006, 12, S130-S130.	0.7	2
859	Contemporary performance of surgical ventricular restoration procedures: Data from the Society of Thoracic Surgeons' National Cardiac Database. American Heart Journal, 2006, 152, 494-499.	1.2	25
860	A centralised telephone intervention reduced combined all cause mortality or admission for worsening HF in chronic heart failure. Evidence-Based Medicine, 2006, 11, 50-50.	0.6	1
861	Implantable left ventricular assist devices: new hope for patients with end-stage heart failure. North Carolina Medical Journal, 2006, 67, 110-5.	0.1	8
862	Left Ventricular Assessment in Myocardial Infarction. Archives of Internal Medicine, 2005, 165, 2162.	4.3	18
863	Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP. Evidence-Based Medicine, 2005, 10, 9-9.	0.6	0
864	Third and fourth heart sounds had low sensitivity but moderate to high specificity for predicting left ventricular dysfunction.. Evidence-Based Medicine, 2005, 10, 182-182.	0.6	1

#	ARTICLE	IF	CITATIONS
865	Hoping for the best while preparing for the worst: Communication about end-of-life planning in Heart Transplant Programs. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, S44.	0.3	0
866	Recurrence of Cardiac Sarcoidosis in a Heart Transplant Recipient. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1988-1990.	0.3	90
867	Outcomes With an Alternate List Strategy for Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1781-1786.	0.3	75
868	Review: Implantable cardioverter defibrillators reduce all-cause mortality in nonischemic cardiomyopathy. <i>ACP Journal Club</i> , 2005, 142, 57.	0.1	0
869	Preoperative Evaluation for Major Noncardiac Surgery. <i>Archives of Internal Medicine</i> , 2004, 164, 1729.	4.3	29
870	Outcomes in heart failure patients after major noncardiac surgery. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1446-1453.	1.2	180
871	Fast Partial-Differential Synthesis of the Matching Polynomial of C72-100. <i>Journal of Chemical Information and Computer Sciences</i> , 1998, 38, 1105-1110.	2.8	14